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Report on Analysis of Quality Related Events (Medication Errors)  
 Reviewed by the Massachusetts Board of Registration in Pharmacy 
January 1, 2004 – December 1, 2004 
 
 
I. Introduction 
 
The mission of the Massachusetts Board of Registration in Pharmacy (Board) is to promote, preserve, and 
protect the public health, safety, and welfare by promoting the provision of quality pharmaceutical care to 
the citizens of Massachusetts through the regulation of pharmacy practice, community pharmacies, and the 
distribution of prescription drugs in the public interest. The Board assumes a leadership role in regulating the 
practice of pharmacy and acts in accordance with the highest standards of ethics, accountability, efficiency, 
effectiveness, and openness.   
 
Chapter 149 of the Acts of 2004 (Fiscal Year 2005 Budget) requires the Board to prepare a compilation of 
cases involving preventable medical error reports received by the board that resulted in harm to a patient or 
health care provider for the purpose of assisting health care providers, hospitals and pharmacies to modify 
their practices and techniques to avoid error.  The Board is statutorily mandated to protect the public health, 
safety and welfare through the licensure of community pharmacies and pharmacists, registration of pharmacy 
interns and technicians, and regulation of the practice of pharmacy. The Board licenses community 
pharmacies pursuant to M.G.L. c. 112, ss. 37-39 and 247 CMR 6.00.  The Board currently licenses 
approximately 1,042 community (retail) pharmacies; seven nuclear pharmacies; 9,940 pharmacists; 6,200 
pharmacy technicians and 65 wholesale drug distributors.    
 
Community pharmacies are not required by statute to report medication errors to the Board; therefore, the 
analysis presented in this report is of consumer complaints received and reviewed by the Board between 
January 1, 2004 and December 1, 2004.  Complaints were reviewed to identify those that involved a 
medication error meeting the definition of a Quality Related Event as set forth in the Board regulation 247 
CMR 15.01.  A Quality-Related Event or QRE means the incorrect dispensing of a prescribed medication 
that is received by a patient, including: 
 
(a)   a variation from the prescriber's prescription order, including, but not limited to: 
1.   dispensing an incorrect drug; 
2.   dispensing an incorrect drug strength; 
3.   dispensing an incorrect dosage form; 
4.   dispensing the drug to the wrong patient; or 
5.   providing inadequate or incorrect packaging, labeling, or directions; or 
(b)   a failure to identify and manage: 
1.   over-utilization; 
2.   therapeutic duplication; 
3.   drug-disease contraindications; 
4.   drug-drug interactions; 
5.   incorrect drug dosage or duration of drug treatment; 
6.   drug-allergy interactions; or 
7.   clinical abuse/misuse. 
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Complaints that involved regulatory violations such as continuing education deficiencies, controlled 
substance violations, or allegations of unprofessional conduct, or any other complaint that did not include 
practice issues meeting the definition of a QRE were excluded from analysis for this report. Reports 
involving hospital/institutional and clinic pharmacies were also excluded from the analysis since those 
pharmacies are licensed by the Massachusetts Department of Public Health Division of Health Care Quality 
and operate under a separate regulatory framework with different reporting requirements administered by the 
Division of Health Care Quality.  
 
Thirty-nine (39) consumer complaints were found to involve a QRE, as defined above.  Those thirty-nine 
(39) cases were separated into the following four Categories of Events: 
 
1. Potential to Cause Harm (P): Dispensing error that reached the patient with no ingestion.  
2. Ingestion with No Harm (I): Dispensing error that reached the patient with ingestion and no harm 
resulting. 
3. Ingestion with Harm (IH): Dispensing error that reached the patient with ingestion and harm 
resulting. 
4. Sentinel Event (S): Dispensing error that reached the patient with ingestion and serious permanent 
harm or death to the patient resulting. 
 
After being separated by Category of Event, the complaints were classified by the Type of Error made during 
prescription preparation and/or dispensing. Each complaint (hereinafter referred to as “case”) was also 
examined to gain a broader understanding of the error and to determine corrective measures taken by the 
pharmacy and pharmacist(s) in response to the error. 
 
The Board believes the findings of this report provide valuable insights into the nature of medication errors 
which occurred within community based pharmacies licensed by the Board.   The findings of this report will 
also be useful in guiding the Board in its efforts to protect the public health, safety and welfare through the 
development and promotion of initiatives that educate pharmacy professionals as to the need for and benefits 
of Continuous Quality Improvement (CQI) programs. 
 
We wish to recognize the thousands of community pharmacy professionals who provide Massachusetts 
citizens with vitally important pharmaceutical services every day and who provide clinical leadership in the 
movement to develop safer practices and better pharmaceutical therapies.  More than eighty-three million 
prescriptions were dispensed in Massachusetts in 20031 and certainly the vast majority of those services were 
delivered without incident.  The thirty-nine (39) complaints involving medication errors that form the basis 
of this report are miniscule in comparison to the millions of prescriptions dispensed, without incident, in 
Massachusetts every year.  Nevertheless, we hope that the findings of this report provide a greater 
understanding of issues involved in prescription preparation and delivery and lead to development of 
strategies to prevent errors.  To that end, we urge pharmacy profession leaders to not only review this report 
for their own benefit, but to widely distribute it within their pharmacies so that all staff may benefit from 
knowledge of factors contributing to the medication errors discussed in this report.  These case analyses 
should be used as a benchmark from which pharmacists examine current practices in their particular 
pharmacy to identify areas where changes or additional safeguards may be appropriate to prevent the 
occurrence of similar errors. 
 
                                                          
1 Pharmacy Journal of New England, Volume 2, Number 2, 2005.  
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This report may be accessed on the Board’s web site at www.state.ma.us/dph/boards/.   Notice of the release 
of this report will be sent to Massachusetts community pharmacies, hospitals, pharmacy associations and 
patient safety organizations, including the Betsy Lehman Center for Patient Safety and Medical Error 
Reduction and the Massachusetts Coalition for the Prevention of Medical Errors. 
  
II. Historical Perspective  
 
Patient safety is at the forefront of concern for all healthcare providers and institutions providing services to 
patients. The spotlight on patient safety evolved from lessons learned from tragic events that resulted in a 
call for cultural change throughout the healthcare industry.  The benchmark report TO ERR IS HUMAN: 
Building a Safer Health System issued by the Institute of Medicine (IOM) Quality of Health Care in America 
Committee2  (the “IOM Report”) in 1999 identified and quantified the need to focus on preventable medical 
errors and system processes as the cause of many errors. In Massachusetts, the Betsy Lehman Center for 
Patient Safety and Medical Error Reduction and the Massachusetts Coalition for the Prevention of Medical 
Errors were established to improve patient safety and reduce the incidence of medical errors by developing 
and disseminating best practices and by facilitating the exchange of information about initiatives under 
development to improve patient care.  
 
The IOM Report and other studies have focused on medical errors (including medication errors) that 
occurred in hospitals, which represents only a portion of the varied settings where health care services are 
provided.    Community pharmacies are an integral part of the health care delivery system providing patients 
with critically important services and counseling for safe and proper medication use. 
 
Major initiatives of the Board that promote the highest standards of pharmacy practice in the Commonwealth 
include: 
 
A.  Best Practice Initiative 
 
In 2000, the Board convened an advisory committee to make recommendations to the Board regarding CQI 
initiatives that could be implemented in all pharmacy practice settings to promote optimum pharmaceutical 
care.  Participants in the Board’s CQI Advisory Committee included Board members and representatives 
from institutional and retail pharmacy settings, professional associations, and schools/colleges of pharmacy, 
the Massachusetts Coalition for the Prevention of Medical Errors, the Department of Public Health and 
related regulatory agencies.  
 
The CQI Advisory Committee developed a set of Best Practice Recommendations that could be 
implemented in various pharmacy settings according to the particular needs, available resources, and 
community served by the pharmacy. These recommendations were developed following a review of current 
literature on medication dispensing systems and research on the incidence and causes of medication errors, 
as presented by the Board’s Quality Assurance Surveyor and CQI Advisory Committee Chairman (a member 
of the Board). The Board has disseminated the Best Practice Recommendations to the regulated community 
at various educational forums statewide and continuously updates the recommendations as additional 
pharmacy practice patterns, high-risk error areas, and technology benefits/challenges are identified.   
 
A summary of the Best Practice Recommendations issued by the Board is provided in Appendix A of this 
report and may be viewed at www.gov/dph/boards/ph/index.htm    
 
                                                          
2 Institute of Medicine, To Err is Human: Building a Safer Health System, National Academy Press, 2000 
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B.  New Pharmacy Board Regulations Requiring Continuous Quality Improvement Programs  
 
The Board believes that establishing CQI Programs in pharmacies is key to reducing the incidence of errors.  
Consequently, the Board promulgated new regulations (247 CMR 15.00) that require pharmacies licensed 
by the Board to establish CQI Programs for the purpose of detecting, documenting, assessing and 
preventing Quality Related Events (QREs).  Pharmacies licensed by the Board are required to implement 
CQI Programs by December 31, 2005.  CQI Program regulations are provided in Appendix B of this report 
and may be viewed at http://www.mass.gov/dph/boards/ph/rule_reg.htm  
 
At a minimum, as required by 247 CMR 15.02(1), a pharmacy CQI program must include provisions to:  
 
1. designate an individual or individuals responsible for monitoring CQI Program compliance 
with the requirements of 247 CMR 15.00; 
2. identify and document QREs; 
3. minimize impact of QREs on patients; 
4. analyze data collected in response to QREs to assess causes and any contributing factors;  
5. use the findings of the analysis to formulate an appropriate response and develop pharmacy 
systems and workflow processes designed to prevent QREs; and 
6. provide ongoing professional education at least annually in the area of  CQI to pharmacy 
personnel.   
 
III. Analysis and Findings 
 
A.  Results by Category of Event  
 
A breakdown by Category is presented below for the thirty-nine (39) consumer complaints analyzed. 
 
Category 1: Potential to Cause Harm (P) - Dispensing error that reached the patient with no 
ingestion. 
 
Seven (7) of thirty-nine (39) cases reviewed were characterized as involving Potential To Cause 
Harm to the patient. Three (3) of these cases involved the dispensing of incorrect medication; three 
(3) involved incorrect strength; and one (1) involved incorrect directions. In all of these cases, the 
QRE was discovered prior to any ingestion by the patient.  Actual impact on patient(s) was 
determined to be at a level of minimal inconvenience that did not cause disruption in planned 
treatment for the patient.   In one case (Case #1/Appendix D), Lipitor 10mg was prescribed and 
Lisinopril 10mg was dispensed.  Lipitor is used to lower cholesterol levels and Lisinopril 10mg is 
used to control elevated blood pressure levels (hypertension).  Although the patient did not ingest the 
medication, the potential for harm existed because ingestion of the incorrect medication for an 
extended period of time would have compromised the intended prescribed treatment for this patient.  
 
Category 2:  Ingestion with No Harm (I) - Dispensing error that reached the patient with ingestion 
and no harm resulting. 
 
Seven (7) of the thirty-nine (39) cases reviewed were characterized as involving Ingestion With No 
Harm to the patient.  Five (5) of these cases involved ingestion of the incorrect medication for a range 
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of 2 to 30 days and two (2) cases involved ingestion of the incorrect strength of the prescribed 
medication for a range of 1 to 30 days.   All of these cases involved a temporary impact on the 
intended treatment but did not require a medical intervention.  For example, a prescription for Zantac 
Syrup was dispensed with Albuterol Syrup to a four-month-old infant (Case #11/Appendix D).  
Zantac is a medication utilized for gastrointestinal conditions and Albuterol is used to treat asthma.  
Although ingestion occurred for a three-day period without negative consequences in this case, the 
intended therapy was disrupted and the patient was exposed to an unintended medication with 
potential risk.  
 
Category 3:  Ingestion with Harm (IH) -Dispensing error that reached the patient with ingestion 
and short term reversible harm resulting. 
 
Twenty-three (23) of the thirty-nine (39) cases reviewed were categorized as involving Ingestion 
With Harm requiring treatment intervention. The ingestion resulted in reversible short-term harm that 
adversely affected intended treatment or required medical intervention.  Medical interventions 
included emergency room visits or revisits to the physician’s office to address mild to moderate side 
effects resulting from disruption in planned treatment.  Nine (9) of these cases involved ingestion of 
the incorrect medication for a range of 1 to 30 days; nine (9) cases involved the dispensing of a 
prescription with the incorrect strength with ingestion for a range of 1 to 60 days; two (2) cases 
involved the dispensing of a medication with incorrect directions with ingestion for 7 and 14 days; 
one (1) case involved ingestion of an incorrectly labeled prescription with ingestion for 14 days; one 
(1) case involved dispensing a medication to the incorrect patient with ingestion for one (1) day; and 
one case involved dispensing a prescription to a patient with a known allergy to medication.  In one 
case (Case #13/Appendix D), a prescription for Tegretol 100mg was incorrectly dispensed with 
Tegretol 200mg to a six-year old. Tegretol is an anticonvulsant medication indicated for the treatment 
of seizures.  Ingestion of a two-fold increased dose occurred over a two-day period. On the third day, 
a 911 call was placed for severe toxicity symptoms requiring admission to an emergency room for 
observation and treatment.  Patients involved in these events received medical interventions and 
appropriate treatment in time to avoid any long-term adverse health affects. 
 
Category 4:  Sentinel Event (S)  - Dispensing error that reached the patient with ingestion and 
serious permanent harm or death to the patient resulting. 
 
Two (2) of the thirty-nine (39) cases reviewed were categorized as involving a Sentinel Event.  In one 
case (Case #2/Appendix D), a prescription for Cardura (doxazosin) 4mg was incorrectly dispensed 
with Coumadin (warfarin) 4mg.  Cardura is indicated for the control of hypertension and Coumadin 
is used for anticoagulation (blood thinning). A 69-year-old patient incorrectly received a blood 
thinning medication instead of high blood pressure medication for approximately one (1) month. The 
patient was admitted to an emergency room and hospitalized for five (5) days for side effects related 
to Coumadin toxicity. The second case in this category involved the dispensing of medication to a 
patient with a known allergy to the dispensed medication involving an anti-inflammatory agent. All 
cases in this category resulted in extended hospitalization with long-term health consequences for the 
patients. 
 
A more detailed summary of each case is provided in Appendix D of this report.   
 
 
 
 
 8
 
B.  Results by Type of Error  
 
Cases were also classified by Type of Error, which includes incorrect medication, incorrect strength, 
incorrect directions, incorrect labeling, incorrect patient, and failure to verify allergy. Additionally, the cases 
were analyzed to identify the probable contributors to the error, such as sound-alike or look-alike 
medications, failure to correctly verify prescription, or failure to perform an adequate drug utilization review 
(DUR). The breakdown of cases by Type of Error follows:  
 
1.  Incorrect Medication – eighteen (18) cases were classified as a prescription dispensed with the 
incorrect medication. 
 
 Ten (10) of these eighteen (18) cases involved sound-alike or look-alike medications as 
follows: 
• Amaryl 2mg rather that Avandia 2mg 
• Chlorpropamide rather than Chlorpromazine 
• Coumadin 4mg rather than Cardura 4mg 
• Lisinopril 10mg rather than Lipitor 10mg 
• Neurontin rather than Zarontin 
• Prilosec 10mg rather than Prozac 10mg 
• Sprintec rather than Tri-Sprintec 
• Zantac Syrup rather than Zyrtec Syrup 
• Zyrtec Syrup rather than Zantac Syrup (2 cases) 
 
 Eight (8) of these eighteen (18) cases involved a failure to correctly verify prescription as 
follows: 
• Albuterol Syrup rather than Zantac Syrup 
• Alprazolam rather than Vioxx 
• Dilantin 100mg rather than Phenytoin 100mg 
• Doxycycline rather than Darvocet 
• Methocarbamol rather than Relafen 
• Monopril rather than Serzone 
• Toprol XL 100mg rather than Seroquel 100mg 
• Trihexyphenidyl rather than Fluphenazine 
 
 Five (5) of these eighteen (18) cases (also included in the above categories) involved age 
specific dosing for children that resulted in the child receiving higher than recommended 
doses of the incorrectly dispensed medication. They include: 
• Albuterol Syrup rather than Zantac Syrup 
• Neurontin rather than Zarontin 
• Zantac Syrup rather than Zyrtec Syrup 
• Zyrtec Syrup rather than Zantac Syrup (2 cases) 
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2.  Incorrect Strength – Fourteen (14) cases were classified as a prescription dispensed with the 
incorrect strength. 
 
 Nine (9) of these fourteen (14) cases involved a drug with the same name as the prescribed 
drug but the incorrect strength of the medication was dispensed, as follows:  
• Atenolol 50mg rather than Atenolol 25mg 
• Ativan 1mg rather than Ativan 0.5mg 
• Clonazepam 1mg rather than Clonazepam 0.5mg 
• Epi-Pen Adult 0.3mg rather than Epi-Pen Junior 0.15mg 
• Haldol 5mg rather than Haldol 0.5mg 
• Zonegran 100mg rather than Zonegran 25mg 
• Phenobarbital 64.8mg rather than Phenobarbital 32.4mg 
• Tegretol 200mg rather than Tegretol 100mg 
• Wellbutrin SR 150mg rather than Wellbutrin 100mg 
 
 Five (5) of these fourteen (14) cases involved failure to correctly verify prescription before 
dispensing, as follows: 
• Augmentin Suspension inadequate reconstitution 
• Cefzil Suspension inadequate reconstitution 
• Hydroquinone 4% with sunscreen rather than Hydroquinone 4% plain 
• Nitroglycerin 2% ointment rather than Nitroglycerin 0.2% ointment 
• Zithromax Suspension inadequate reconstitution 
 
 Five (5) of these fourteen (14) cases (also included in the above categories) involved age 
specific dosing for children resulting in the child receiving the incorrect strength of the 
prescribed medication, as follows: 
• Augmentin Suspension inadequate reconstitution 
• Epi-Pen Adult 0.3mg rather than Epi-Pen Jr. 0.15mg 
• Tegretol 200mg rather than Tegretol 100mg 
• Zithromax Suspension inadequate reconstitution 
• Zonegran 100mg rather than Zonegran 25mg 
 
3.  Incorrect Directions – Three (3) cases were classified as a prescription dispensed with incorrect 
directions.  All three (3) of these cases involved failure to correctly verify prescription directions, 
as follows:  
• Allopurinol 300mg, Take 4 tablets daily rather than 1 tablet daily 
• Clonazepam 0.5mg, Take 4 tablets at bedtime rather than 6 tablets at bedtime 
• Paxil 40mg, Take 2 tablets daily rather than 1 tablet daily 
 
4.  Incorrect Labeling – Two (2) cases were classified as incorrect labeling of a prescription. One 
case involved a failure to correctly verify two prescriptions for the same patient. Specifically, a 
Carafate prescription was labeled with Protonix directions and vice versa for the Protonix 
prescription. As a result, the patient ingested both medications in incorrect amounts for a two-
week period prior to discovery. The second case (Case #9/Appendix D) involved two types of 
errors, specifically, incorrect labeling on a prescription that was also dispensed to the incorrect 
patient. In this case, the medication Zithromax suspension was both incorrectly labeled and 
incorrectly dispensed to a 5-year old patient.  
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5. Incorrect Patient - One (1) case was classified as a prescription dispensed to the incorrect patient. 
This case involved a failure to perform an adequate drug utilization review (DUR) involving a 
prescription with age specific dosing; specifically, a prescription for Zithromax suspension with a 
600mg dose (adult dose) was dispensed rather than the prescribed 190mg (pediatric dose) to a 5 
year-old child.  Although the correct labels specific to the adult and child patients were generated, 
an error occurred during the label placement process resulting in the correct label being placed on 
the packaging box (child’s label) and an incorrect label being placed on the actual suspension 
bottle inside the box (adult label).  As a result, the medication was administered as directed on the 
incorrect label affixed to the bottle, leading to vomiting by the child. 
 
6. Failure to Verify Allergy – Two (2) cases involved a failure to perform an adequate drug 
utilization review (DUR) which resulted in the dispensing of a prescription to a patient with 
known allergy to medication.  Both patients had documented allergies to the prescribed 
medication; one involved an anti-inflammatory agent (naproxen) and the other involved a 
benzodiazepine (lorezapam). 
 
C.  Corrective Actions  
 
As part of its complaint review, the Board requires involved pharmacists and pharmacies to conduct a QRE 
post-event analysis and describe corrective actions taken to prevent recurrence.  In addition, each pharmacist 
involved in an error is required to complete a Board approved continuing education course in medication 
error prevention.  The involved pharmacies are required to submit a medication error report to a nationally 
recognized reporting program, such as the reporting systems operated by U.S. Pharmacopoeia (USP), the 
Institute for Safe Medication Practices (ISMP), and the U.S. Food and Drug Administration (FDA).   
 
Corrective action plans submitted to the Board in response to the cases reviewed in this report address the 
factors identified by the pharmacists and pharmacy as related to the QRE and detail the actions taken by the 
pharmacists and pharmacy to prevent recurrence.  When developing a plan for corrective actions, 
pharmacists and pharmacies commonly review pharmacy policy and procedures pertaining to: 
 
1. Prescription data entry; 
2. Prescription verification, including review of technologies available such as bar code scanning and 
medication imaging; 
3. Drug utilization review; and  
4. Patient counseling procedures. 
 
A summary of corrective actions taken in response to specific cases analyzed in this report is provided in 
Appendix D of this report. 
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IV. Conclusions and Recommendations 
 
A.  Conclusions 
 
This report analyzes thirty-nine (39) consumer complaints involving medication errors that were reviewed by 
the Massachusetts Board of Registration in Pharmacy from January 1, 2004 to December 1, 2004.  More 
than eighty-three million prescriptions were dispensed in Massachusetts in 2003.2  The numbers of 
complaints involving medication errors that form the basis of this report are miniscule in comparison to the 
millions of prescriptions dispensed, without incident, in Massachusetts every year.  Nevertheless, we hope 
the analysis presented in this report provides a greater understanding of issues in prescription preparation and 
delivery.  This is the Board’s most comprehensive effort to date to analyze and compile complaints reviewed 
by the Board as part of its ongoing efforts to identify and address the causes and contributors to the 
occurrence of medication errors in community setting.  A common reason cited by a patient or consumer in 
filing a complaint with the Board in the aftermath of an error is the desire for pharmacies and pharmacists 
take necessary corrective action after an error to prevent recurrence.  Communicating our analysis and 
findings with the pharmacy community is intended for use in the development of effective strategies to 
prevent errors from occurring.  The identification of medication error QREs through the complaint review 
process also underscores the importance of developing a “partnership in care” relationship between 
consumers, pharmacists and prescribing practitioners to reduce the incidence of errors. There is a pressing 
need to establish CQI programs in community-based pharmacies, similar to the quality assurance and error 
prevention initiatives that have been widely implemented in hospital pharmacies.  Patients deserve and 
expect safe and accurate pharmacy practices across the Commonwealth.    
 
Efforts to communicate with licensees and the public about specific patient safety issues identified by the 
Board are ongoing.  When the Board identifies a high-risk error pattern, the Board has published newsletter 
articles highlighting the specific medications involved in those types of errors.  A recent article written by 
Board members warning of concerns about the sound-alike drugs Zantac (ranitidine) and Zyrtec (certirizine) 
was published in the August 2004 Board newsletter (see Appendix C of this report). The Board notes that the 
National Association of Boards of Pharmacy, the FDA, drug manufacturers, state, local and specialty 
pharmacy associations, and patient safety organizations also have recognized the importance of developing 
effective strategies to reduce the incidence of errors.  Advancements in technology, prescription labeling, 
manufacturing processes and regulatory policy will also assist in the elimination and reduction of errors.  
 
Errors in drug dispensing that involve factors such as sound-alike and look-alike drugs, failure to perform 
adequate drug utilization review (DUR), missed opportunities for correction of error at final verification, 
factors such as failure of pharmacy personnel to utilize available technology specifically designed to reduce 
errors, and significant gaps in providing direct and effective patient counseling by the pharmacist, are a few 
of the root contributors that must be addressed to prevent errors from occurring and recurring.   
Micro bar coding implemented during the manufacturing process to identify individual tablets may also 
provide a double check to ensure that the labeled vial correlates with the contents, thus reducing errors 
involving incorrect medication and incorrect strength.  Improved standards for the appearance and names of 
products at the drug approval phase may also prevent medication errors related to sound-alike, look-alike 
medications.  Pharmacists must also be diligent in providing patients and their caregivers with effective 
counseling and key information about the proper use and administration of their medications.   Involving 
patients in their care and educating them about their prescribed medications is absolutely necessary to reduce 
the overall incidence of medication errors. 
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The important process of implementing CQI programs in community pharmacies that include methods for 
identifying and understanding root causes of errors is a critically important initiative that will improve 
internal pharmacy systems and build greater consumer confidence in the pharmaceutical services provided 
by Massachusetts pharmacists and community pharmacies.  In conjunction with this effort, community 
pharmacies are encouraged to establish non-punitive medication error reporting systems that promote the 
reporting of errors and “near misses” by employees to allow for follow up review in order to gain an 
understanding of what happened and what steps can be taken to prevent a recurrence.   A collaboration of 
health care providers dedicated to the identification, prevention and education of root causes of error will 
achieve the safest pharmaceutical services for patients. 
 
B.  Recommendations 
 
In furtherance of its goal to promote safe practice and improve the delivery of pharmacy services in the 
Commonwealth, the Board will seek to: 
 
1. Assist and advise pharmacists and community pharmacies in implementing Continuous Quality 
Improvement Program Regulations (247 CMR 15.00), requiring community pharmacies to establish 
CQI programs by December 31, 2005.  CQI programs must identify, document and analyze data 
collected in response to QREs; assess causes and any contributing factors; formulate an appropriate 
response and develop pharmacy systems and workflow processes designed to prevent QREs; provide 
ongoing professional education at least annually in the area of CQI to community pharmacy personnel; 
and designate an individual or individuals responsible for monitoring CQI Program compliance. 
 
2. Develop a Quality Related Event (Medication Error) Prevention Training Program to educate and assist 
pharmacists and community pharmacies in complying with new CQI program regulations.  This 
training program will address methods and techniques for conducting a root cause analysis, as well as 
the design, implementation and monitoring of corrective action plans.  
 
3. Explore options for convening an expert consensus group in collaboration with the Betsy Lehman 
Center for Patient Safety and Medical Error Reduction and the Massachusetts Coalition for the 
Prevention of Medical Errors to study medication errors in community-based settings for purposes of 
developing best practice guidelines.  
 
4. Collaborate with the Betsy Lehman Center for Patient Safety and Medical Error Reduction to consider 
development of methodologies for collecting and analyzing medication error and “near miss” reports 
for all pharmacy settings. 
 
5. Continue to circulate “Best Practice Recommendations to Promote Optimum Pharmaceutical Care in 
the Commonwealth of Massachusetts” and encourage pharmacists and pharmacies to implement the 
recommendations. These Best Practices are posted on the Board’s website and are updated periodically 
to address emerging issues pertaining to the practice of pharmacy.  
 
6. Communicate with the colleges/schools of pharmacy to develop curriculum content that incorporates    
   continuous quality improvement and patient centered risk management theories as well as techniques   
   for quality related event discovery, analysis and reporting. 
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Appendix A: 
Best Practice Recommendations to Promote Optimum Pharmaceutical Care in the 
Commonwealth of Massachusetts 
 
In 2000, the Massachusetts Board of Registration in Pharmacy (Board) convened an advisory committee to 
make recommendations to the Board regarding continuing quality improvement (CQI) initiatives that could 
be implemented in all pharmacy practice settings to promote optimum pharmaceutical care.  Participants in 
the Board’s CQI Advisory Committee included Board members, representatives from institutional and retail 
pharmacy settings, professional associations, colleges of pharmacy, the Massachusetts Coalition for the 
Prevention of Medical Errors, the Department of Public Health and related regulatory agencies.  
 
The CQI Advisory Committee developed a set of Best Practice Recommendations (Recommendations) that 
could be implemented by the various pharmacy settings according to the particular needs, available 
resources, and community served by the pharmacy.  The Recommendations developed by the CQI Advisory 
Committee were based on a review of current literature on medication dispensing systems and recent 
research on the incidence and causes of medication errors, as presented by the Board’s Quality Assurance 
Surveyor and CQI Advisory Committee Chairman (a member of the Board).  The CQI Advisory Committee 
provided comment and direction regarding the Recommendations and forwarded the proposed 
Recommendations to the Board for adoption.  
 
The Board adopted these Best Practice Recommendations on September 25, 2001 (amended on various 
dates thereafter) as recommended standards of professional practice to be considered for 
implementation as appropriate by pharmacies to promote optimum pharmaceutical care outcomes in 
the Commonwealth.  
 
The Recommendations cover most pharmacy settings and include a variety of measures that can be 
implemented immediately and other processes that involve technological and training topics that can be 
instituted over a longer period of time to improve medication delivery systems.  This list is not exclusive of 
other improvements that may be necessary to a particular pharmacy setting and may be supplemented by the 
Board from time to time.  
 
The Board urges all pharmacies to make review of these recommendations a high priority and to 
consider implementation of those measures that are appropriate to the particular pharmacy setting.  
The Board believes that adoption and institution of these practices will result in improved 
performance, increased patient safety, a reduction in medication errors, and enhanced pharmacy 
medication delivery systems in general.  
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MASSACHUSETTS BOARD OF REGISTRATION IN PHARMACY 
 
Best Practice Recommendations  
To Promote Optimum Pharmaceutical Care  
in the Commonwealth of Massachusetts  
 
1. Develop policies and procedures providing that incident reports will be completed and submitted 
to a national database, such as the USP Medication Errors Reporting Program (MERP), for each 
quality-related event (QRE) occurrence.  A QRE is defined as any departure from the appropriate 
dispensing of a prescribed medication that is not corrected prior to the delivery of the medication. 
The term “quality-related event” includes variations from the specifications of a prescription, such 
as wrong drug, wrong strength, wrong directions, and wrong dosage form.  The term also includes 
packaging or warnings that fail to meet recognized standards, the delivery of a medication to the wrong 
patient, and the failure to detect and appropriately manage a significant actual or potential problem with 
a patient’s drug therapy. 
 
 Recommended Actions  
9 Create a system for reporting medication errors to a national database to promote analysis of the 
occurrence of the QRE and prevent similar events from recurring.  
9 Promote a non-punitive atmosphere for reporting of medication errors. 
9 Voluntarily report QRE to the USP Medication Error Reporting Program.   
 
2. Institute a system to quarterly review incident reports generated at the pharmacy.  Perform      
root cause analysis and include information from such review in quality improvement programs.   
Reviewers should include pharmacists, pharmacy technicians, and appropriate management 
personnel. 
 
 Recommended Actions  
9 Evaluate the QREs that occurred in the pharmacy on a quarterly basis and identify the root cause of 
the QREs. 
9 Implement improvements/interventions based on the information gathered as part of the root cause 
analysis. 
9 Publicize changes to pharmacy staff. 
 
3. Develop and implement an effective workflow plan that is evaluated periodically to maximize 
effective use of space, equipment and staff. 
 
 Recommended Actions  
9 Develop policies and procedures to ensure that the appropriate individuals are completing appropriate 
tasks. 
9 Consider the use of automated devices to aid staff. 
9 Explore ways to optimize patient care services, i.e. providing separate area for confidentiality when 
counseling patients. 
9 Evaluate the size of the pharmacy to determine optimum dispensing area. 
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4. Routinely poll customers regarding quality of care and satisfaction with service. 
 
 Recommended Actions  
9 Develop a customer-focused survey to identify areas of improvement. 
9 Review the findings of the survey with pharmacy staff to develop solutions to improve patient 
satisfaction. 
 
5. Develop and implement a comprehensive technician-training program that requires pharmacy 
technician trainees to demonstrate competence in functioning as pharmacy technicians and to 
qualify for registration as pharmacy technicians.  
 
 Recommended Actions 
9 Develop a comprehensive pharmacy technician training program and provide a copy of the technician 
training program to the Board’s Technician Training committee for Board approval. 
9 Encourage pharmacy technicians registered by the Board to meet and maintain certification 
requirements. 
9 Provide continuing education opportunities for pharmacy technicians. 
 
6. Implement a policy requiring that counseling be offered to every patient receiving a prescription, 
regardless of whether the prescription is new or a refill.  During patient counseling, the 
pharmacist should verify that the patient understands the purpose, proper use and expected 
outcomes of their drug therapy.   Counseling should also include information as to the safe and 
accurate use of prescribed medications.  Educating patients about the safe and effective use of 
medications promotes patient involvement in their own care and is an important component of 
any medication error reduction strategy.  Patient counseling may have a beneficial impact by 
reducing the incidence of quality-related events. 
 
 Recommended Actions  
9 Dispense or recommend proper measuring device (e.g., oral dosing spoon) with all liquid 
medications.  Instruct patients or caregivers on how to use the measuring device. 
9 Provide written patient drug information materials with all new outpatient prescriptions dispensed. 
9 Develop standard counseling procedures that include checks for the following: 
¾ Right patient 
¾ Right drug 
¾ Right drug for this patient 
¾ Appropriate dosing schedule 
¾ Appropriate route of administration 
¾ Correct route of administration for this patient 
¾ Verification that the patient understand why they are taking the drug  
¾ Verification that the patient understands how to use the drug 
 
7. Develop policies and procedures that insure patient profiles are periodically updated for drug 
allergies, patient weight, adverse reactions, over-the-counter (OTC) medication usage, and 
alternative medication/herbal remedy usage. 
 
 Recommended Actions  
9 Develop a policy that requires that allergy information be updated when filling or refilling a 
prescription. 
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9 Require all new prescriptions include allergy information.  
9 Develop a policy of updating  patients weight  periodically   
9 Ask patients about their use of OTC medications and herbal remedies and document responses in the 
patient profile. 
9 Update patient profiles periodically.  Updates should include information on newly developed 
allergies even if patient is not filling a new prescription. 
 
8. Utilize available age and weight adjusted dosing guidelines when appropriate. 
 
 Recommended Actions  
9 Verify pediatric dosing to ensure proper dose. 
9 Develop pediatric and geriatric specific guidelines for age and weight adjusted dosing. 
9 Consider acquiring or utilizing reference materials, textbooks and/or computer software that directly 
address pediatric and geriatric dosing. 
9 When appropriate and necessary, verify that doses are appropriate for the patient. 
 
9. Provide adequate and easy access to appropriate reference materials.  
 
 Recommended Actions  
9 Provide Internet access to pharmacists to research clinical information. 
9 Establish a clinical department to serve as a resource for dispensing pharmacists. 
9 In addition to required reference texts, provide additional reference materials, such as computer 
software programs, relevant to particular practice setting. 
 
10. When necessary and appropriate, question adherence to prescriber directions when a medication 
intended for chronic use is filled more than three days late or when the medication is reordered 
substantially earlier than expected. 
 
 Recommended Actions  
9 Monitor prescription drug usage among chronic disease state patients to ensure compliance. 
9 Ask the patient if a drug therapy change has occurred and if needed contact the prescriber to obtain 
updated information. 
9 Ask patients how they are feeling, paying attention to improvements in the patient’s condition as well 
as adverse effects. 
 
11. Develop written policies and procedures to assure that outdated stock or stock with an expiration 
date that does not allow sufficient time for dispensing by the pharmacy or use by the patient is 
segregated from other stock and either prepared for return to the manufacturer or destroyed 
and documented. 
 
 Recommended Actions 
9 Periodically inspect the expiration date on the medication stock bottles. 
9 Periodically inspect the expiration date on the medication containers in the refrigerator or freezer. 
9 Identify short dated items with a colored label indicating expiration date. 
9 Check expiration dates on all products prior to completing the filling and dispensing of medication.  
 
12. Adopt written policies and procedures pertaining to the handling of filled prescription orders 
waiting for pick-up by a patient or patient representative. 
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 Recommended Actions 
9 Verify the patient’s name, address, and date of birth when prescription orders are picked up. 
 
13. Adopt written policies and procedures relating to the return of unclaimed prescriptions to stock.  
 
 Recommended Actions  
9 Adopt a policy that only a pharmacist may return medication to the stock with appropriate checks. 
 
14. Develop procedures to ensure drug recalls are acted upon in a timely manner.   
 
 Recommended Actions  
9 Adopt procedure that personnel receiving recall notice are required to immediately bring the recall 
notification to the pharmacist’s attention. 
 
15. Explore the reasons for out of stock items.  
 
 Recommended Actions  
9 Collect data and analyze trends related to out of stock items. 
9 Utilize a computer program to determine inventory employing maximum/ minimum strategy. 
9 Consider auto replenishment technology.   
9 Refer to the FDA shortage list 
 
16. Adopt a policy allowing for continuation of therapy for out of stock or unavailable items.    
 
 Recommended Actions 
9 Inform patient or caregiver that the medication is out of stock or unavailable. 
9 If known, inform patient or caregiver when the medication would be available. 
9 Offer to make arrangements for the patient or caregiver to pick up the medication at another location. 
9 If the availability from manufacturer will result in interruption of therapy, offer to call the physician 
to discuss a change in therapy. 
 
17. Adopt a policy allowing pharmacists up to a thirty-minute lunch break when they work six or  
 more hours in a day. 
 
  Recommended Actions  
9 Develop policies and procedures regarding the operation of the pharmacy during the temporary 
absence of the pharmacist for breaks and meal periods, in accordance with policies of the Board of 
Registration in Pharmacy. 
9 Develop policies and procedures detailing the authorized duties of ancillary staff during temporary 
absences of the pharmacist; the pharmacist’s responsibilities for checking all work performed by 
ancillary staff; and the pharmacist’s responsibility for maintaining the security of the pharmacy.  
 
18. Develop policies and procedures regarding proper staffing.   
 
 Recommended Actions  
9 Periodically review staffing requirements to assure adequate availability of professional, technical 
and clerical staff. 
9 Ensure that available and competent staff is available during periods of high activity. 
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19. Utilize interpreters as necessary.   
 
 Recommended Actions  
9 Employ individuals who can speak a second language. 
9 Learn a second language. 
9 Engage an interpreter service (such as AT&T). 
 
20. Develop policies and procedures, which continually improve pharmacy, practice by incorporating 
strategies to optimize therapeutic outcomes. 
 
 Recommended Actions  
9 Consider disease state management programs and certification programs to enhance delivery of 
pharmaceutical care.  
9 Initiate a program to monitor HbA1C levels of diabetic patients. 
9 Counsel patients with diabetes regarding the proper use of glucose monitoring equipment, insulin, 
syringes, injection techniques, and insulin pens. 
9 Implement a program to encourage high-risk patients to have cholesterol levels evaluated. 
9 Encourage patients with asthma to demonstrate proper use of Metered Dose Inhalers (MDIs), spacers, 
and peak-flow meters. 
9 Institute and promote procedures to determine if patients utilizing chronic care medications are adhering 
to prescribed medical regimens. 
9 Develop a plan for the acquisition of adherence software within an acceptable time frame. 
9 Provide counseling and conduct activities to help increase immunization rates for patients at high risk 
for pneumonia and influenza.   
 
21. Develop policies and procedures, which continually insure the integrity of Biologicals and  
 Pharmaceuticals.  
 
 Recommended Action 
9 Consider maintaining a daily temperature log on file to insure proper storage of biologicals and 
refrigerated pharmaceuticals  
 
22. Develop and implement written policies and procedures that enhance anti-counterfeiting measures 
regarding the receipt, storage and security of controlled substances.  
 
 Recommended Actions  
9 Visually examine all deliveries promptly on receipt to identity contents and determine if any 
contaminated, damaged, misbranded, expired and or suspected  counterfeit drugs or devices are 
included in the shipment. 
9 Quarantine any drugs or devices found to be unacceptable for further examination and 
determination.  
9 Inspect medication during final verification to assure product accuracy and integrity.  
9 Request wholesalers to certify that all medications delivered to the pharmacy, not accompanied by 
a pedigree, are purchased directly from the manufacturer.  
9 Report suspected counterfeit medications to MedWatch (the FDA Safety Information and Adverse 
Event Reporting Program), the Board and appropriate law enforcement authorities within three 
business days. 
9 Educate consumers about the risks of counterfeit medications.  
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9 Encourage consumers to promptly consult with health care professionals if they suspect that their 
medication is counterfeit.  
9 Remind consumers to be aware of noticeable differences in their medications or packaging and the 
occurrence of any adverse events.  
9 Alert consumers to the important role pharmacists play in identifying, reporting and responding to 
counterfeit drug events.  
9 Advise consumers to make online medication purchases from pharmacies that have obtained the 
Verified Internet Pharmacy Practice Site (VIPPS) seal from the National Association of Boards of 
Pharmacy (NABP).  
9 Maintain records of counterfeit reports from manufacturers and other sources for a minimum 
three-year period. 
9 Consult NABP’s “National Specified List of Susceptible Drug Products” available for reference at 
www.nabp.org and the Board’s website under “Board News” at www.mass.gov/reg/boards/ph. 
 
23. Develop and implement written policies and procedures regarding the identification of medication 
when requested by a consumer/patient or medical professional. 
 
Resources for Non-Emergency Product Identification Requests  
[If emergency call poison control center at 1-800-222-1222] 
 
 Recommended Actions  
 
1. When a prescription is associated with the medication to be identified. 
9  Verify the prescription content with the original copy of the prescription dispensed making sure that 
the markings on the unidentified medication match the prescription medication dispensed and 
identified from the original prescription. 
 
9  If unidentified medication can not be verified then refer to procedure #2. 
 
2. Identification of a medication with manufacturer’s code and/or NDC code or other markings
 on the product. 
9  Utilize available resources and references (see Attachment A) to identify 
 medication by manufacturers’ identification codes, NDC code, or drug name. 
 
9  If medication cannot be identified then refer to procedure #3. 
 
3. Identification of a medication that has no markings and/or is a formulation (liquid) that is not 
positively identifiable. 
9  Call the poison control center and describe medication and indication for use if known. 
(EMERGENCY SITUATION)  
 
9  In non-emergency situations, obtain services for laboratory product analysis, 
http://www.bostonanalytical.com or http://www.bio-concept.com 
 
 
 
 
 
 
 21
 
Attachment A 
 
Online resources for identifying prescription and non-prescription drugs:  
 
• http://www.drugdigest.org click on to Drug library then pill images. * 
• http://www.drugs.com/ identifies by, name, codes and/or description. * 
• http://www.rxlist.com/interact.htm identifies by code, drug name, or Manufacturer. * 
• http://www.drugs.com/manufacturers.html links to Medication manufacturers. * 
• PDRhealth, The Drug Information Directory. * 
• Prescription drugs http://www.pdrhealth.com/drug_info/rxdrugprofiles/alphaindexa.shtml * 
• OTC drugs http://www.pdrhealth.com/drug_info/otcdrugprofiles/alphaindexa.shtml * 
• www.mcphs.edu/altmed Center for Complementary and Alternative Pharmacotherapy. * 
• http://www.micromedex.com/  Micromedex  
• http://www.cp.gsm.com/ Clinical Pharmacology Product Identification 
• http://www.identadrug.com/ by Pharmacist Newsletter 
* information accessed without charge 
 
Books for identifying drugs may be available at your local public or university library:  
• Ident-A-Drug Reference; identifies drugs by the numbers, letters and images.  
• Mosby's DrugConsul 
• Physicians' Desk Reference (PDR) 
• Facts and Comparisons 
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Appendix B 
247 CMR 15.00: CONTINUOUS QUALITY IMPROVEMENT PROGRAM 
 
Section 
15.01:   Definitions 
15.02:   Continuous Quality Improvement Program 
15.03:   Quality Related Event Discovery, Notification and Documentation 
15.04:   Records 
 
15.01:   Definitions 
 
Continuous Quality Improvement Program or CQI Program means a system of standards and 
procedures to identify and evaluate quality-related events and improve patient care. 
 
Quality-Related Event or QRE means the incorrect dispensing of a prescribed medication that is 
received by a patient, including: 
(a)   a variation from the prescriber's prescription order, including, but not limited to: 
1.   dispensing an incorrect drug; 
2.   dispensing an incorrect drug strength; 
3.   dispensing an incorrect dosage form; 
4.   dispensing the drug to the wrong patient; or 
5.   providing inadequate or incorrect packaging, labeling, or directions; or 
(b)   a failure to identify and manage: 
1.   over-utilization; 
2.   therapeutic duplication; 
3.   drug-disease contraindications; 
4.   drug-drug interactions; 
5.   incorrect drug dosage or duration of drug treatment; 
6.   drug-allergy interactions; or 
7.   clinical abuse/misuse. 
 
Pharmacy, as referenced in 247 CMR 15.00, means a pharmacy, or a group of pharmacies under 
common ownership and control of one entity, licensed by the Board pursuant to M.G.L. c. 112. 
 
Pharmacy Personnel means pharmacist, pharmacy intern, pharmacy technician and pharmacy 
support personnel. 
 
15.02:   Continuous Quality Improvement Program 
 
(1)   Continuous Quality Improvement Program Requirements.  Each pharmacy shall establish a 
Continuous Quality Improvement (CQI) Program for the purpose of detecting, documenting, 
assessing and preventing Quality-Related Events (QREs).  At a minimum, a CQI program shall 
include provisions to: 
(a)   designate an individual or individuals responsible for monitoring CQI Program 
compliance with the requirements of 247 CMR 15.00;  
(b)   identify and document QREs;  
(c)   minimize impact of QREs on patients; 
(d)   analyze data collected in response to QREs to assess causes and any  contributing 
factors;  
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(e)   use the findings of the analysis to formulate an appropriate response and develop 
pharmacy systems and workflow processes designed to prevent QREs; and 
(f)   provide ongoing education at least annually in the area of CQI to pharmacy personnel.  
 
(2)   Implementation Date.  The CQI Program requirements of 247 CMR 15.00 shall be 
implemented by each pharmacy by December 31, 2005. 
 
15.03:   Quality Related Event Discovery, Notification and Documentation 
 
(1)   QRE Discovery and Notification.  All pharmacy personnel shall be trained to bring any 
QRE to the attention of the pharmacist on duty or the pharmacist Manager of Record 
immediately upon discovery. The pharmacist who has discovered or been informed of a QRE 
shall immediately provide: 
(a)   notification to the patient or patient's representative, the prescriber (if indicated in the 
professional judgment of the pharmacist) and other members of the healthcare team; 
(b)   directions for correcting the error; and  
(c)   instructions for minimizing the negative impact on the patient.  
 
(2)   QRE Documentation. 
(a)   A QRE shall be initially documented by the pharmacist who has discovered or been 
informed of the QRE on the same day the QRE is discovered by or described to the 
pharmacist.  
 
(b)   QRE documentation shall include a description of the event that is sufficient to permit 
categorization and analysis of the event.  QRE documentation shall include: 
1.   the date when the pharmacist discovered or received notification of the QRE and the 
name of the person who notified the pharmacy; 
2.   the names and titles of the persons recording the QRE information and performing 
the QRE analysis; 
3.   a description of the QRE reviewed; and  
4.   documentation of the contact with the patient, or patient’s representative, and 
prescribing practitioner (if indicated in the professional judgment of the pharmacist), and 
other members of the healthcare team. 
 
(3)   QRE Analysis and Response. 
(a)   QRE Analysis.  The investigative and other pertinent data collected in response to QREs 
shall be analyzed, individually and collectively, to assess the cause and any contributing 
factors such as system or process failures. The QRE analysis and assessment shall include: 
1.   a consideration of the effects on quality assurance related to workflow processes, 
technological support, personnel training and staffing levels;  
2.   any recommended remedial changes to pharmacy policies, procedures, systems, or 
processes; and 
3.   the development of indicators that identify means against which a pharmacy’s 
program intends to measure its standards over a designated period of time. 
(b)   Response.  Each pharmacy shall inform pharmacy personnel of changes to pharmacy 
policies, procedures, systems, or processes resulting from recommendations generated by the 
CQI Program. 
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15.04:   Records 
 
(1)   Each pharmacy shall maintain a written copy of its CQI Program description on the 
pharmacy premises.  The CQI Program description shall be readily available to all pharmacy 
personnel. 
 
(2)   Each pharmacy shall maintain a record of all QREs for a minimum period of two years 
from the date of the QRE report. 
 
 
(3)   QRE records shall be maintained in an orderly manner and filed by date.   
 
(4)   QRE records may be stored at a site other than the pharmacy where the QRE occurred.  
 
 
REGULATORY AUTHORITY 
 
247 CMR 15.00:  M.G.L. c. 112, §§ 37 through 39 and 42A. 
 
 
CQI Regulations are available at http://www.mass.gov/dpl/boards/ph/cmr.htm  
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Appendix C  
Article Written by Board Members and Published in the Massachusetts Board of 
Registration in Pharmacy August 2004 Newsletter 
 
Mix-ups in Zantac/Zyrtec 
By Karen Ryle and Donna Horn 
 
In Massachusetts, as well as other parts of the country there have been numerous errors that have occurred in 
the pediatric population where ZANTAC (ranitidine) syrup (Glaxo Wellcome) has been prescribed but 
ZYRTEC (cetirizine) syrup (Pfizer) has been dispensed. Zantac is an H2 receptor blocker and Zyrtec is an 
H1 antihistamine. Although these medications do not have overlapping dosage strengths, both are available 
in the syrup dosage form: Zantac as 150 mg/10 mL and Zyrtec as 5 mg/5 mL. Since a different company 
manufactures each drug, the container labels look dissimilar. However, the syrups of both drugs are available 
in 480 mL amber glass bottles. Zyrtec syrup is also available in a 120 mL bottle. The proprietary names look 
and sound alike, increasing the potential for medication errors. 
Errors occurred most frequently in patients ranging in ages from 7 days to 15 months. In one case, a 12-
month-old male patient was prescribed 120 mL of Zantac syrup but was given 120 mL of Zyrtec. The error 
occurred when the incorrect stock bottle of Zyrtec syrup was chosen by the technician and poured into the 
dispensing bottle labeled as Zantac. The mother noticed that the baby became "violently ill" but the doctor 
did not find any serious injury after examining the baby. In another case, a 15-month-old patient was given 
Zyrtec instead of Zantac for 6 weeks before the error was discovered. The patient's reflux-induced sinusitis 
continued until the error was corrected. Other patients experienced sleep disturbances, increased thirst, 
decreased appetite, diarrhea, vomiting, and decreased weight as a result of the errors. Thankfully, none of the 
symptoms caused serious harm to patients.  
SAFE PRACTICE RECOMMENDATION: 
• Separate stock bottles of Zantac and Zyrtec syrups in pharmacy dispensing areas and any other areas 
in the healthcare facility where the drugs are stored* (e.g., automated dispensing cabinets). 
•  Encourage prescribers to include the drug's indication to differentiate these look-alike drug names 
and reduce the risk of selecting the wrong drug due to poor handwriting*.  
• As with all liquid oral medications, physicians should include the desired mg/mL concentration to 
guide proper drug selection, especially since the drug concentrations differ*.  
• The dose should also be expressed in mg, not just volume (mL or teaspoonfuls). Place reminders on 
stock bottles and install pharmacy computer alerts to advise staff of the risk for errors*.  
• It's also helpful to warn patients about the risk of confusing these two products so they can detect 
possible errors when filling prescriptions.  
• As a final check, immediately before the patient or caregiver leaves the pharmacy department with 
the filled prescription, open the bottle and sniff the liquid. Does it smell like mint? Then it must be 
Zantac. What does the label indicate it is supposed to be? 
*Institute for Safe Medication Practices. Action needed to prevent dangerous Zyrtec-Zyprexa mix-ups. ISMP Medication Safety 
Alert! Volume 5, Issue 22 November 1, 2000.  Similar sound-alike, look-alike mix-ups have occurrence with Zyrtec and 
Zyprexa™ tablets – be mindful 
 
http://www.mass.gov/dpl/boards/ph/forms/ma082004.pdf 
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Appendix D 
Analysis of Quality Related Event (Medication Error) Reports Reviewed by the Massachusetts Board 
of Registration in Pharmacy January 1, 2004 – December 1, 2004  
 
 
A.   Definitions of Column Headings in Appendix D 
 
Column 1 Case #.  Case number identifier of particular case. 
 
Column 2 Category of Event. Each Quality Related Event  (QRE) is classified in one of the 
following four (4) categories:  
 
P -  Potential to Cause Harm.   Medication error that reached the patient with no ingestion. 
 
I -  Ingestion with No Harm.  Medication error that reached the patient with ingestion and no 
harm resulting.  
 
IH - Ingestion with Harm.  Medication error that reached the patient with ingestion and harm 
resulting.  
 
S - Sentinel Event.   Medication error that reached the patient with ingestion and serious 
permanent harm or death to the patient resulting. 
 
Column 3 Date. The date the case was entered into the information technology databank system 
utilized by the Board. 
 
Column 4 Case Description.  Summary description of the specific medication and details of the error 
involved in the particular QRE. 
 
Column 5 Type of Error.   Further description of the specific type of error involved in the QRE, 
such as: 
 
Incorrect Directions 
Incorrect Labeling 
Incorrect Medication 
Incorrect Patient 
Incorrect Strength 
Failure to Verify Allergy 
 
Column 6 Patient Outcomes.  Summary description of the specific patient outcomes in the QRE. 
 
Column 7 Corrective Action.  Summary description of the information provided to the Board by the 
pharmacists and pharmacies involved in the QRE regarding specific actions taken after 
identification of the error.  For example, a root cause analysis may have been performed by 
involved personnel to determine why the event occurred and how to prevent the event from 
recurring.  Information on contributing factors to the QRE as well as corrective action plans 
focused on prevention of similar events in the future may also be submitted to the Board. 
Pharmacies also submit a medication error report to a national data bank such, as the reporting 
 29
systems operated by the Institute for Safe Medication Practices (ISMP) (http://www.ismp.org) 
and the United States Pharmacopoeia (USP) (http://www.usp.org). Pharmacists complete 
Accreditation Council for Pharmacy Education (ACPE) approved continuing education units on 
medication error prevention and provide continuing education compliance history for the previous 
licensure cycle. 
 
  
B.  Glossary of Terms and Acronyms used in Appendix D  
 
ACPE.   Accreditation Council for Pharmacy Education.  
(http://www.acpe-accredit.org) 
 
Board.  Massachusetts Board of Registration in Pharmacy.  
 
CEU or Continuing Education Unit.  A unit of measure of educational credit equal to ten contact 
hours or its equivalent, as determined by the Board, of satisfactory participation in a Board-approved 
program of continuing education. (247 CMR 2.00) 
 
CQI Program or Continuous Quality Improvement Program.  A system of standards and 
procedures to identify and evaluate quality-related events and improve patient care.   
(247 CMR 2.00) 
 
DUR or Drug Utilization Review.  A medication profile review performed by a pharmacist to verify 
drug indications, drug allergies, dose, route, amount, drug-drug/drug food interactions and 
appropriate lab monitoring of medications prescribed. 
 
IOM or Institute of Medicine.  A nonprofit organization established to act as adviser to the nation to 
improve health. (http://www.ism.org) 
 
ISMP or Institute for Safe Medication Practices.  A nonprofit organization that works closely with 
healthcare practitioners and institutions, regulatory agencies, professional organizations and the 
pharmaceutical industry to provide education about adverse drug events and their prevention. 
(http://www.ismp.org) 
 
ITD.  An information technology databank system utilized by the Board.  
 
NDC or National Drug Code Number.  The nationally recognized standard that identifies drug 
products using a unique number issued by the U. S. Food and Drug Administration. The NDC has 
three components: the first component identifies the drug manufacturer ("Labeler No."); the second 
component identifies the product ("Product No."); and the third component identifies the package 
size ("Pkg."). (247 CMR 2.00) 
 
Prescription. An order for a drug, chemical, device or combination thereof, either written, given 
orally or otherwise transmitted to a registered pharmacy by a practitioner or his or her expressly 
authorized agent, to be dispensed or compounded in a registered pharmacy and dispensed by a 
registered pharmacist to a patient or his or her agent with necessary and appropriate counseling.         
(247 CMR 2.00) 
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Prescription Drug. Any and all drugs which, under federal law, are required, prior to being 
dispensed or delivered, to be labeled with the statement: "Caution, Federal law prohibits dispensing 
without prescription" or “Rx only” and a drug which is required by any applicable Federal or State 
law or regulation to be dispensed pursuant only to a prescription drug order. (247 CMR 2.00) 
 
QRE or Quality Related Event. The incorrect dispensing of a prescribed medication that is received 
by a patient, including: 
(a)   a variation from the prescriber's prescription order, including, but not limited to: 
1.   dispensing an incorrect drug; 
2.   dispensing an incorrect drug strength; 
3.   dispensing an incorrect dosage form; 
4.   dispensing the drug to the wrong patient; or 
5.   providing inadequate or incorrect packaging, labeling, or directions; or 
(b)   a failure to identify and manage: 
1.   over-utilization; 
2.   therapeutic duplication; 
3.   drug-disease contraindications; 
4.   drug-drug interactions; 
5.   incorrect drug dosage or duration of drug treatment; 
6.   drug-allergy interactions; or 
7.   clinical abuse/misuse. (247 CMR 15.01) 
 
Root Cause Analysis.  A process to determine the factors that contributed to the QRE. By repeatedly 
asking why at each level of the cause and effect to determine what processes, procedures or training 
contributed to the event, changes can be made to prevent medication errors.  
 
USP/ISMP Medication Error Report.  Reports of QREs may be provided to the national USP 
Medication Errors Reporting (MER) Program operated by the United States Pharmacopoeia (USP) 
(http://www.usp.org) and the Institute for Safe Medication Practices (ISMP).  This voluntary error 
reporting program seeks to help prevent medication errors through the collection and dissemination 
of information about their circumstances and causes.  
 
 
 
APPENDIX D: Analysis of Quality Related Event (Medication Error) Reports Reviewed by the Massachusetts Board of Registration in Pharmacy 
 
 
Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
1 
 
P 
 
01/02/04 
 
Lisinopril 10mg 
dispensed in place 
of Lipitor 10mg. 
Lisinopril 10mg is an 
ACE inhibitor 
(angiotension 
converting enzyme 
inhibitor) utilized to 
control 
hypertension. Lipitor 
10 mg is a 
cholesterol-lowering 
agent. 
 
Incorrect 
Medication 
 
Negative patient 
outcomes involving 
adverse effects from 
receiving maintenance 
doses of Lisinopril 
incorrectly are symptoms 
of annoying cough, 
angioedema and low 
blood pressure. Other 
consequences due to 
lack of treatment with 
Lipitor would include 
possible increase in 
cholesterol levels.  
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) “Baker Cassette” procedure (automated medication retrieval 
system) reviewed for correct medication retrieval.  
2) Medication verification process reviewed.  
3) CEUs completed on "Prescription Errors and Legal Responsibility" 
of a pharmacist.  
4) Submitted ISMP medication error report.  
5) Completed CEU on “Medication Error Prevention”. 
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
2 
 
S 
 
01/16/04 
 
A prescription for 
Cardura 4mg 
indicated for the 
control of 
hypertension was 
incorrectly 
dispensed with 
Coumadin 4mg 
indicated for 
anticoagulation 
(blood thinner).  
 
Incorrect 
Medication
 
A 69-year-old patient 
incorrectly received 
Coumadin 4mg for an 
approximate period of 
one month. The patient 
was admitted to an 
emergency room and 
hospitalized for five days 
for side effects related to 
Coumadin toxicity. The 
patient was diagnosed 
with a small vessel 
(Lacuna) stroke.   
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) Prescription verification process. The pharmacist will verify the 
medication filled, verify the original hard copy of the prescription, 
then verify the directions and match the NDC numbers of the 
medication against the NDC numbers of the filled medication.  
2) Verification of labels on all containers dispensed utilizing bar code 
scanning technologies will be followed. 
3) Patient counseling procedure.  Prescription will be reviewed with 
the patient to verify the correct medication and directions. 
4) Communication of error to all pharmacy personnel and all 
pharmacies within the corporation.  
5) Submitted an ISMP medication error report. 
6) Completed continuing education on “Medication Error Prevention”. 
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
3 
 
S 
 
02/11/04 
 
Naproxen, a NSAID 
(non-steroidal anti-
inflammatory drug), 
was dispensed to 
patient with allergy 
to this class of 
medication. 
Pharmacy 
conversion to new 
computer program 
failed to flag patient 
allergy.  
 
Failure to 
Verify 
Allergy  
 
Naproxen was ordered 
by the physician and 
dispensed to a patient 
who was allergic to 
NSAIDS. The patient 
ingested five doses of 
Naproxen. The patient 
developed a severe rash 
and blistering of the skin. 
The patient was 
hospitalized with a 
diagnosis of toxic 
epidural necrolysis and 
transferred to the burn 
unit with 70% skin 
involvement due to drug 
induced reaction.  
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians. 
1) Data Entry Process. All patient profiles for the facility where patient 
resided were reviewed and corrected as needed for correct drug 
allergy data entry.  
2) Faxed Orders. Policy and procedures were reviewed.  
3) Allergy fields on faxed orders reviewed and corrected as needed. 
4) New order verification process. All new medications orders will be 
checked for allergies.  
5) Final Check verification process. Scanning technology will be 
utilized when verifying orders against allergies listed on profile. 
6) Submitted an ISMP medication error report.  
7) Completed continuing education on “Medication Error Prevention”.  
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
4 
 
I 
 
03/11/04 
 
A prescription for 
Ativan 0.5mg was 
incorrectly 
dispensed with 
Ativan 1mg. The 
pharmacy 
dispenses 
medications utilizing 
the "blister pack" 
system. The correct 
label was affixed to 
the incorrect 
strength of Ativan. 
 
Incorrect 
Strength 
 
A prescription for Ativan 
0.5 mg was incorrectly 
dispensed with Ativan 
1mg to an elderly patient. 
A two-fold increase in 
dose was ingested for 
two doses prior to 
discovery by a nurse at a 
long-term care facility.  
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians. 
1) Data Entry Process. A computer upgrade will be installed to 
include imaging software, a visual display of drug verification and 
bar code scanning of product. 
2) Faxed Orders. Policy and procedures reviewed. 
3) Medication packaging "blister pack" system* reviewed and bar 
code scanning of label and card for verification process will be 
used prior to labeling. 
4) Communication. Error was shared with all pharmacy personnel. 
5) Final Check verification process. Scanning technology will be 
utilized when verifying orders. 
6) Submitted an ISMP medication error report. 
7) Completed continuing education on “Medication Error Prevention”. 
 
*Blister pack system is a multiple quantity packaging system. 
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
5 
 
IH 
 
05/04/04 
 
A prescription for 
Cefzil Suspension, 
an antibiotic, was 
reconstituted with 
insufficient amount 
of water resulting in 
a higher 
concentration of 
dose.  
 
Incorrect 
Strength 
 
An infant received a 
concentrated dose of 
Cefzil Suspension for a 
period of four days in 
error due to the improper 
reconstitution of the 
medication. The infant 
suffered stomach distress 
and was seen by the 
pediatrician. The mother 
made the discovery after 
noticing an insufficient 
supply for a ten day 
course of antibiotic  
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) Proper reconstitution of suspensions reviewed utilizing a calibrated 
water dispenser. 
2) Prescription verification. Reconstituted products will be visually 
inspected for appropriate consistency. 
3) Dispensing procedures reviewed.  
4) Patient counseling procedure reviewed. 
5) Communication. Error information was shared with all pharmacy 
personnel and all pharmacies within the corporation.  
6) Submitted an ISMP medication error report 
7) Completed continuing education on “Medication Error Prevention”. 
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
6 
 
IH 
 
05/04/04 
 
Ativan 0.5mg was 
prescribed, 
dispensed and 
administered to a 
patient who was 
allergic to 
benzodiazepines. 
 
Failure to 
Verify 
Allergy  
 
Ativan 0.5mg was 
ordered, dispensed and 
administered in a long 
term care facility. The 
patient had a 
documented allergy to 
benzodiazepines 
recorded on pharmacy 
and nursing charts.  
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) Patient records have been updated with all allergies and allergies 
will be verified with original physician’s order.  
2) Verification of labels on all containers dispensed.  
3) Communication, this error was shared with all pharmacy 
personnel. 
4) Submitted an ISMP medication error report. 
5) Completed continuing education on “Medication Error Prevention”. 
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
7 
 
IH 
 
05/05/04 
 
Haldol 5mg, an 
antipsychotic drug, 
was incorrectly 
dispensed for Haldol 
0.5mg tablets.  
 
Incorrect 
Strength 
 
A prescription for Haldol 
0.5 mg was incorrectly 
dispensed with Haldol 
5mg to a 14-year-old 
patient. Ingestion 
occurred and the patient 
had side effects requiring 
admission to an 
emergency room. The 
side effects of a ten-fold 
increase in dose can be 
mild to severe. 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians. 
1) During product selection the pharmacist will carry the hard copy 
(new prescription) or label (refill prescription) to the shelf to verify 
the product selected against the hardcopy or verify the NDC 
against the refill label. Using pharmacies look-alike-sound-alike 
system.  
2) Separated the different strengths of Haldol with a yellow check 
NDC sticker.  
3) Communicated to pharmacy staff the importance of making the 
pharmacy more organized and efficient to prevent prescription 
errors from occurring. 
4) Reduce the pressure on pharmacist by having technicians assist 
as much as they can with the fill process: entering prescriptions, 
calling insurance companies and ordering. 
5) A medication error report submitted to ISMP. 
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
8 
 
IH 
 
05/20/04 
 
Two prescriptions 
for Carafate and 
Protonix for the 
same patient were 
labeled and 
dispensed 
incorrectly due to 
cross labeling. Both 
medications are 
indicated for the 
treatment of ulcers. 
 
Incorrect 
Labeling 
 
The Carafate prescription 
had the directions for the 
Protonix prescription and 
vice versa for the 
Carafate prescription. As 
a result, the patient 
ingested both 
medications incorrectly 
for a period of two weeks 
prior to discovery.  The 
patient complained of 
feeling ill and required a 
follow-up appointment 
with primary physician. 
The patient ingested a 
four-fold increase of 
Protonix and a four-fold 
reduction in prescribed 
dose of Carafate. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) DUR review on all prescriptions for allergies, drug interactions and 
dosing. 
2) Prescription image scanning for identification. 
3) Barcode scanning to verify prescription. 
4) Staffing. Pharmacist shift overlap coverage. 
5) Policy and Procedure review. 
6) Submitted an ISMP medication error report.   
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
9 
 
IH 
 
05/20/04 
 
A prescription for 
Zithromax Oral 
Suspension, an 
antibiotic, was 
dispensed with the 
incorrect patient's 
name and 
directions. 
 
Incorrect 
Patient 
 
 
A prescription was 
incorrectly dispensed to a 
five-year-old child 
resulting in a three-fold 
increase in the dose of 
the intended medication 
Zithromax Oral 
Suspension. The label on 
the suspension bottle 
directed a 600mg dose 
rather than the 
prescribed 190mg dose. 
The incorrect dose 
caused an acute episode 
of vomiting before the 
error was corrected. The 
prescription included two 
separate labels  - one 
(incorrect amount and 
incorrect patient) 
attached to the 
prescription bottle and 
the second (correct) 
attached to the 
packaging box.  
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) Prescription verification process. The pharmacist will verify the 
medication filled, verifying the original hard copy of the 
prescription, then verifying the directions and matching the NDC 
numbers of the medication against the NDC numbers of the filled 
medication.  
2) Verification of labels on all containers dispensed. 
3) Patient counseling procedure. The prescription will be reviewed 
with the patient to verify the correct medication and directions. 
4) Communication. Error was shared with all pharmacy personnel 
and all pharmacies within the corporation. 
5) Submitted an ISMP medication error report. 
6) Completed continuing education on “Medication Error Prevention”. 
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
10 
 
IH 
 
05/26/04 
 
A prescription for 
Serzone 200mg, an 
antidepressant, was 
incorrectly 
dispensed with 
Monopril 40mg, an 
antihypertensive. 
 
Incorrect  
Medication
 
The patient ingested two 
doses of the incorrect 
medication Monopril. The 
patient became dizzy, 
lightheaded and tired and 
experienced a fall with 
subsequent shoulder 
pain. Symptoms of 
hypotension are 
consistent with the 
patient's complaint.  
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) NDC cross verification on stock bottle, label and receipt by 
highlight, circle or underlining the NDC number. 
2) A root cause analysis was submitted that identified prescription 
identification and verification process failure as root contributors.  
3) Medication references reviewed. 
4) Submitted ISMP medication error report. 
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
11 
 
I 
 
05/26/04 
 
A prescription for 
Zantac Syrup, 
indicated for the 
treatment of ulcers 
or gastroesophogeal 
reflux disease 
(GERD), was 
incorrectly 
dispensed with 
Albuterol Syrup, a 
bronchodilator used 
to control asthma. 
 
Incorrect 
Medication
 
A refill prescription for 
Zantac Syrup was 
incorrectly dispensed to a 
4-month-old infant with 
Albuterol Syrup. 
Ingestion occurred for a 
three-day period before 
discovery by parent. 
Potential for harm exists 
due to ingestion of the 
unintended medication. 
The potential side effects 
are mild to severe and 
can include 
sleeplessness, agitation 
and abnormal cardiac 
effects. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians. Adherence to basket 
system. 
1) Medications dispensed from liquid stock bottles are entered into 
the computer so the stock bottle can be scanned.  
2) Stock bottle remains in the basket throughout the dispensing 
process. 
3) The stock bottle is checked against the printed label. 
4) All prescriptions for liquids are opened and eyed carefully at 
verification point. 
5) Imaging scanning is checked with liquid stock bottles. 
6) Review of technician training. 
7) Submitted ISMP medication error report. 
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
12 
 
IH 
 
06/08/04 
 
A prescription for 
Omeprazole 10mg, 
indicated for 
gastroesophogeal 
reflux disease 
(GERD), was 
incorrectly 
dispensed with 
Fluoxetine 10mg, an 
antidepressant. 
Patient ingested the 
incorrect medication 
for 14 days. 
 
 
Incorrect 
Medication 
 
The potential for harm 
exists due to the length of 
time the incorrect 
medication was taken 
prior to discovery. The 
14-day period is the time 
it usually takes for the 
medication Fluoxetine to 
begin having a 
therapeutic effect and 
reach blood levels 
capable of exhibiting a 
response. The side 
effects from Fluoxetine 
range from mild to 
severe.   
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) Prescription verification process. The pharmacist will verify the 
medication filled, verifying the original hard copy of the 
prescription, then verifying the directions and matching the NDC 
numbers of the medication against the NDC numbers of the filled 
medication.  
2) Verification of labels on all containers dispensed utilizing bar code 
scanning technologies will be followed.  
3) Patient counseling procedure. The prescription will be reviewed 
with the patient to verify the correct medication and directions. 
4) Communication. Error was shared with all pharmacy personnel 
and all pharmacies within the corporation. 
5) Submitted an ISMP medication error report. 
6) Completed continuing education on “Medication Error Prevention”. 
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
13 
 
IH 
 
06/08/04 
 
Prescription for 
Tegretol 200mg 
tablets was 
incorrectly 
dispensed instead 
of Tegretol 100mg 
tablets.  
 
Incorrect 
Strength  
 
Tegretol 200 mg, an 
anticonvulsant with a 
high alert narrow 
therapeutic index 
medication utilized for the 
control of seizures, was 
incorrectly dispensed to a 
six year old instead of 
Tegretol 100mg. The 
patient ingested a two-
fold increase in dose for 
two days when 
symptoms of toxicity 
presented. A 911 call 
was placed on day three 
for severe symptoms of 
toxicity requiring 
admission to ER for 
observation and 
treatment.  
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
In this case, the pharmacy did not scan the prescription NDC number 
to the stock bottle resulting in the contents of the prescription not 
matching the labeled strength. The pharmacy has initiated a three-
point checking system.  
1) Every prescription NDC number is scanned into the computer. 
2) The NDC numbers are visually checked to verify that they match 
the product being dispensed. 
3) Every prescription dispensed is visually checked so that the 
prescription contents match the label on the bottle. 
4) Communication. Error was shared with all pharmacy personnel. 
5)  Submitted an ISMP medication error report. 
6) Completed continuing education on “Medication Error Prevention”. 
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
14 
 
IH 
 
06/28/04 
 
Zantac syrup was 
incorrectly 
dispensed in place 
of Zyrtec syrup. 
Zantac syrup 
contains ranitidine 
15mg/ml indicated 
for the treatment of 
ulcers or 
gastroesophogeal 
reflux disease 
(GERD). Zyrtec 
syrup contains 
cetirizine 1mg/ml 
indicated for allergic 
rhinitis or chronic 
urticaria (rash). 
 
Incorrect 
Medication 
 
An eight-year-old patient 
ingested 22 days of the 
incorrect medication 
Zantac syrup prior to 
discovery by a parent. 
Negative patient outcome 
is two fold. Lack of 
efficacy of intended 
medication originally 
prescribed and exposure 
of medication not 
intended for use. The 
medication Zyrtec is 
prescribed for the relief of 
allergy symptoms. The 
negative impact to patient 
was the emergent 
symptoms of allergies. 
Exposure to an 
unintended prescribed 
medication (Zantac) may 
also cause mild to severe 
side effects. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
Corrective action plan:  
1) The separation of Zyrtec and Zantac on the shelf. 
2) Diagnosis will be requested to match drug with treatment 
condition. 
3) Voice mail prescriptions will be checked with faxed copy. 
4) Verification process reviewed.  
5) Drug Utilization Review (DUR) process reviewed.  
6) Quality assurance process reviewed. 
7) Patient counseling procedure reviewed.  
8) Incident with corrective action has been communicated to staff.  
9) Submitted an ISMP medication error report.  
10) Completed continuing education on “Medication Error Prevention”. 
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
15 
 
IH 
 
07/13/04 
 
A prescription for 
Zonegran 25mg was 
incorrectly 
dispensed with 
Zonegran 100mg. 
 
Incorrect 
Strength 
 
The ingestion of the 
incorrect strength (four- 
fold increase) of 
Zonegran to a four year-
old patient occurred over 
a two-month period prior 
to discovery and, resulted 
in symptoms of 
drowsiness, lethargy and 
irritability, missed school 
and an urgent follow-up 
neurology evaluation. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
Corrective action plan was submitted that identified product selection, 
NDC number and dose verification process failures as root 
contributors.  
1) Pharmacist will verify the NDC number by highlighting and 
checking on all prescriptions dispensed. 
2) Communication of error and staff training regarding system 
changes. 
3) Submitted an ISMP medication error report. 
4) Completed continuing education on “Medication Error Prevention”. 
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
16 
 
P 
 
07/06/04 
 
A prescription for 
Zarontin Syrup 
250mg/5ml was 
incorrectly 
dispensed with 
Neurontin Syrup 
250mg/5ml.  
 
Incorrect 
Medication
 
The incorrect medication 
Neurontin Syrup was 
dispensed in place of 
Zarontin Syrup to a nine-
year-old patient. Parent 
discovered the error four 
days after the 
prescription was filled. 
Both medications are 
indicated for epilepsy at 
different doses and both 
have side effects that 
require monitoring. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
Corrective action plan submitted identified failure to receive and read 
back verbal prescription and circumvention of the DUR “duplication of 
therapy” warning as root contributors. 
1) Reviewed the DUR policy for “duplicate therapy”. Pharmacist 
reviewed the importance of the DUR process and the need to 
reconcile all warnings prior to filling a prescription.  
2) Pharmacist and technician reviewed the policy on verbal orders 
and to read back all verbal orders to double check accuracy. 
3) Submitted an ISMP medication error report. 
4) Completed continuing education on “Medication Error 
Prevention”. 
  
APPENDIX D: Analysis of Quality Related Event (Medication Error) Reports Reviewed by the Massachusetts Board of Registration in Pharmacy 
 
 
Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
17 
 
I 
 
07/09/04 
 
A prescription for 
Seroquel 100mg, an 
antipsychotic, was 
incorrectly 
dispensed with 
Toprol XL 100mg, 
an antihypertensive.
 
Incorrect 
Medication 
 
The medication Toprol 
XL 100mg was 
incorrectly dispensed and 
ingested for two doses by 
the patient. The potential 
to cause harm existed in 
the form of possible 
lowered blood pressure 
relative to the patient's 
baseline blood pressure. 
The patient was also 
deprived adequate 
treatment with the 
intended medication 
Seroquel.   
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
Corrective action plan:  
1) Reviewing company’s work flow procedures for filling 
prescriptions. 
2) Obtaining patient information at the drop-off window while the 
patient is physically present.  
3) Matching printed label with their hard copy after label prints and 
matching NDC numbers on the label with NDC number stock drug. 
4) Keeping bench clear of unnecessary clutter.  
5) Utilize computer in verification process of the directions, DUR and 
cross checking typed label against hardcopy and drug dispensed. 
6) Staff communication of error and corrective action plan. 
7) Submitted an ISMP medication error report.  
8) Completed continuing education on “Medication Error Prevention”. 
  
APPENDIX D: Analysis of Quality Related Event (Medication Error) Reports Reviewed by the Massachusetts Board of Registration in Pharmacy 
 
 
Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
18 
 
IH 
 
08/02/04 
 
A prescription for 
Alprazolam 0.5mg, 
an anxiolytic, was 
incorrectly 
dispensed for Vioxx, 
an anti-
inflammatory. 
 
Incorrect 
Medication 
 
The medication 
Alprazolam, indicated for 
the control of anxiety, 
was incorrectly 
dispensed to an 82-year-
old patient who had the 
same last name of the 
patient for whom the 
prescription was 
intended. The medication 
was ingested for four 
days causing lethargy 
and sedation.  Excessive 
sedation had the 
potential to create an 
unsafe episode for this 
patient in the form of 
unsteady gait and 
possible fall as well as 
the lack of arthritis 
medication. The potential 
for Alprazolam to interact 
with several of the other 
medications taken by the 
patient could also be 
clinically relevant. 
 
 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
A root cause analysis was submitted that identified patient 
identification and verification process failure as root contributors. 
1) During the DUR process, the computer will check the dosage 
against the patient’s name and date of birth. NDC cross 
verification on stock bottle, label and receipt.  
2) Verification of labels on all containers dispensed. 
3) Patient counseling the prescription will be reviewed with the 
patient to verify the correct name, medication and directions. 
4) Communication. Error was shared with all pharmacy personnel 
and all pharmacies within the corporation. 
5) Submitted an ISMP medication error report. 
6) Completed continuing education on “Medication Error 
Prevention”. 
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
19 
 
IH 
 
08/04/04 
 
A prescription for 
Phenobarbital 64.8 
mg was incorrectly 
dispensed with 
Phenobarbital 32.4 
mg.   
 
Incorrect 
Strength  
 
The patient received the 
correct drug  
(Phenobarbital) but at 
half the strength 
prescribed resulting in 
sub-therapeutic treatment 
for seizure control. The 
patient ingested 58 
tablets of the wrong dose 
for approximately one 
month before having a 
grand-mal seizure and 
was taken to a local 
emergency facility. 
Phenobarbital 64.8mg is 
a round, scored, white 
tablet with the imprint 
"5013v". Because of the 
size of the imprint and 
the glare of the lighting, 
the "5012v" on the 
incorrectly dispensed 
32.4mg tablet was 
misread as "5013v" (the 
imprint on the prescribed 
64.8mg tablet). 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) Verification processed reviewed.  
2) Patient’s history review and verify scanned hardcopy of 
prescription (use zoom feature). 
3) NDC cross verification on stock bottle. 
4) Physically verify contents of prescription. 
5) Pharmacy Policy and Procedures reviewed for medication 
dispensing process, medication errors, verification process and 
DUR process. 
6) Medication references reviewed. 
7) Submitted ISMP medication error report.  
8) Completed continuing education on “Medication Error Prevention”. 
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Case # 
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of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
20 
 
IH 
 
09/02/04 
 
Zyrtec syrup was 
incorrectly 
dispensed in place 
of Zantac syrup. 
Zantac syrup 
contains ranitidine 
15mg/ml indicated 
for the treatment of 
ulcers or GERD 
(gastroesophogeal 
reflux disease). 
Zyrtec syrup 
contains cetirizine 
1mg/ml indicated for 
allergic rhinitis or 
chronic urticaria 
(rash). 
 
Incorrect 
Medication
 
This error occurred in a 
two-month-old patient 
who received 30 days of 
the incorrect medication 
Zyrtec syrup that was 
discovered by a parent 
on refill. Lack of efficacy 
of intended medication 
originally prescribed and 
exposure to medication 
not intended for use were 
implications for patient 
outcomes, including 
undue sedation of 
patient.  
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) Adherence to basket system. Medications dispensed from liquid 
stock bottles are entered into the computer so the stock bottle can 
be scanned. 
2) Stock bottle remains in the basket throughout the dispensing 
process. 
3) The stock bottle is checked against the printed label. 
4) All prescriptions for liquids are opened and eyed carefully at 
verification point. 
5) Imaging scanning is checked with liquid stock bottles. 
6) Shelf dividers are placed between Zantac and Zyrtec. 
7) The medication error and corrective action plan was 
communicated to staff. 
8) Submitted ISMP medication error report. 
9) Completed two CEUs in "Medication Error Prevention". 
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Case # 
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of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
21 
 
IH 
 
09/09/04 
 
A prescription for 
Augmentin 
Suspension Extra 
Strength 600mg/5ml 
was incorrectly 
reconstituted with 
insufficient amount 
of water resulting in 
a higher 
concentration of 
dose dispensed. 
 
Incorrect 
Strength 
 
The Augmentin 
Suspension Extra 
Strength 600mg/5ml was 
mixed with half of the 
required water for 
reconstitution. The five 
year-old patient received 
five days of medication 
before parent discovery 
of the thick consistency. 
The patient was seen by 
the pediatrician for 
evaluation.  
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians. 
1) Reconstitution of suspensions utilizing the “Fillmaster” water 
dispenser. 
2) Prescription verification. Reconstituted products will be visually 
inspected for appropriate consistency. 
3) Dispensing procedures reviewed. 
4) Patient counseling procedure reviewed. 
5) Communication. Error was shared with all pharmacy personnel 
and all pharmacies within the corporation. 
6) Submitted an ISMP medication error report. 
7) Completed continuing education on “Medication Error 
Prevention”. 
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Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
22 
 
IH 
 
09/15/04 
 
A prescription for 
Zithromax 
Suspension, an 
antibiotic, was 
incorrectly 
reconstituted with 
insufficient amount 
of water resulting in 
a higher 
concentration of 
dose dispensed. 
 
Incorrect 
Strength 
 
A three year-old child 
received an incorrectly 
concentrated dose of 
Zithromax. The child 
developed stomach 
cramps and vomited. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) Proper reconstitution of suspensions reviewed utilizing a calibrated 
water dispenser. 
2) Prescription verification. Reconstituted products will be visually 
inspected for appropriate consistency. 
3) Dispensing procedures reviewed. 
4) Patient counseling procedure reviewed. 
5) Submitted an ISMP medication error report. 
6) Completed continuing education on “Medication Error Prevention.” 
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Type of 
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Corrective Actions  
 
23 
 
IH 
 
09/24/04 
 
Zantac syrup 
incorrectly 
dispensed in place 
of Zyrtec syrup. 
Zantac syrup 
contains ranitidine 
15mg/ml indicated 
for the treatment of 
ulcers or 
gastroesophogeal 
reflux disease 
(GERD). Zyrtec 
syrup contains 
cetirizine 1mg/ml 
indicated for allergic 
rhinitis or chronic 
urticaria (rash). 
 
Incorrect 
Medication
 
This error occurred in a 
child who received three 
days of the incorrect 
medication Zantac syrup 
that was discovered by 
parent. The child suffered 
side effects of abdominal 
pain, gagging, vomiting 
and a prolonged 
nosebleed. Lack of 
efficacy of intended 
medication originally 
prescribed and exposure 
of medication not 
intended for use were 
implications for patient 
outcomes. Emergent 
symptoms of allergies 
from lack of prescribed 
Zyrtec may be mild to 
severe in nature. Impact 
of exposure to Zantac 
may be mild to severe in 
nature. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) Adherence to basket system. Medications dispensed from liquid 
stock bottles are entered into the computer so the stock bottle can 
be scanned. 
2) Stock bottle remains in the basket throughout the dispensing 
process. 
3) The stock bottle is checked against the printed label. 
4) All prescriptions for liquids are opened and eyed carefully at 
verification point. 
5) Imaging scanning is checked with liquid stock bottles. 
6) Shelf dividers are placed between Zantac and Zyrtec. 
7) The medication error and corrective action plan was 
communicated to staff. 
8) Submitted ISMP medication error report. 
9) Completed approved CEUs in "Medication Error Prevention". 
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Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
24 
 
P 
 
09/27/04 
 
A prescription for 
Paxil 40mg daily 
was prescribed and 
Paxil 40mg twice 
daily was incorrectly 
labeled and 
dispensed due to a 
failure to verify a 
poorly written 
prescription. 
 
Incorrect 
Directions 
 
The outcome of the error 
could have caused 
potential harm due to a 
two-fold increase in 
prescribed dose. The 
maximum recommended 
daily dose of Paxil is 
60mg and the incorrect 
directions indicated two 
doses of 40 mg per day  
(80mg per day total). 
Increased potential for 
side effects occurs at 
higher than 
recommended doses. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians. Corrective action plan 
submitted identified poorly written prescription, circumvention of the 
DUR high dose warning and failure to consult prescriber as root 
contributors. 
1) Prescription verification process. The pharmacist will verify the 
original prescription hard copy for appropriate dose and directions 
relevant to the medication dispensed. Pharmacist reviewed policy 
and procedures for prescription verification and the importance to 
never override warning flags without clarification of prescription. 
2) Reviewed the Drug Utilization review (DUR) policy for 
minimum/maximum dose check. 
3) Prescribing physician has been consulted and has agreed to 
clarify future prescriptions to prevent future misinterpretation. 
4) Submitted an ISMP medication error report.  
5) Completed continuing education on “Medication Error 
Prevention”. 
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Type of 
Error 
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Corrective Actions  
 
25 
 
P 
 
10/01/04 
 
A prescription for 
Epi-pen Jr. 0.15mg 
was incorrectly 
dispensed with Epi-
pen 0.3mg. The 
attached label 
directions were 
correct for the 
medication; 
however, the label 
was attached to the 
wrong formulation 
strength of Epi-pen. 
 
Incorrect 
Strength 
 
The incorrect strength of 
Epi-pen (autoinjector) 
was dispensed 
incorrectly at a dose two 
times the prescribed 
dose for an 18-month-old 
patient. Epi-pen 0.3mg 
was dispensed for Epi-
pen Jr. 0.15mg. Epi-pen 
contains epinephrine 
utilized in emergencies 
for severe allergic 
reactions or life 
threatening anaphylaxis. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians. Corrective action plan 
was submitted that identified product selection, NDC number and dose 
verification process failures as root contributors.  
1) Pharmacist will verify the NDC number by highlighting and 
checking on all prescriptions dispensed. 
2) Communication of error and staff training regarding system 
changes. 
3) Submitted an ISMP medication error report. 
4) Completed continuing education on “Medication Error Prevention”. 
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Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
26 
 
IH 
 
10/04/04 
 
A compounded 
prescription for 
Nitroglycerin 0.2% 
Ointment was 
incorrectly 
dispensed with 
Nitroglycerin 2% 
Ointment. 
 
Incorrect 
Strength 
 
The incorrect strength of 
Nitroglycerin Ointment 
was dispensed to the 
patient and applied as 
directed. The ten-fold 
increase in dose resulted 
in the patient 
experiencing side effects 
of headache and 
dizziness. The incident 
was reported to physician 
for appropriate follow-up 
evaluation and care. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians. Corrective action plan 
submitted identified failure in data entry and verification of the 
Nitroglycerin compounded product against the prescription. The 
pharmacist only verified the NDC number on the stock ointment tube 
with the label that was entered incorrectly. Counseling was not offered. 
1) Data entry, after the prescription is entered in the computer the 
original hard copy will follow the final product for verification. 
2) The pharmacist will verify the medication filled, verifying the 
original hard copy of the prescription, then verifying the directions 
and matching the NDC numbers of the medication against the 
NDC numbers of the filled medication. 
3) Patient counseling procedure. The prescription will be reviewed 
with the patient to verify the correct medication and directions. 
4) Communication. Error was shared with all pharmacy personnel. 
5)  Pharmacy will implement the “Best Practices” criteria into policy.  
6) Submitted an ISMP medication error report. 
7) Completed continuing education on “Medication Error 
Prevention". 
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27 
 
IH 
 
10/25/04 
 
An original 
prescription for 
Clonazepam 0.5mg/ 
Take six tablets at 
bedtime and one 
tablet as needed 
was incorrectly 
labeled and 
dispensed with 
Clonazepam 0.5mg/ 
Take four tablets at 
bedtime and one 
tablet as needed. 
On refill, the error 
was discovered but 
then filled incorrectly 
with Clonazepam 
1mg/ Take six 
tablets at bedtime 
and one tablet as 
needed (incorrect 
strength). The 
prescription error 
was discovered by 
patient and 
subsequently 
corrected. 
 
Incorrect 
Label 
 
A prescription was 
incorrectly labeled and 
dispensed with the wrong 
directions for the 
medication Clonazepam. 
The patient received a 
sub-therapeutic dose of 
the intended medication 
for two weeks requiring a 
follow up with the 
physician. The patient 
discovered the error at 
the time of refill, which 
was also dispensed 
incorrectly with the 
incorrect strength (see 
case # 28). The potential 
for harm exists due to the 
inadequate treatment of 
the intended dose 
prescribed by the 
physician. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians. 
1) Data Entry Process. New scanners will be utilized to scan hard 
copies of prescriptions.  
2) Prescription verification process. The pharmacist will verify the 
medication filled, verifying the original hard copy of the 
prescription, then verifying the directions and matching the NDC 
numbers of the medication against the NDC numbers of the filled 
medication. 
3) Verification of labels on all containers dispensed. 
4) Patient counseling procedure, the prescription will be reviewed 
with the patient to verify the correct medication and directions. 
5) Communication. Error was shared with all pharmacy personnel. 
6) Submitted an ISMP medication error report. 
7) Completed continuing education on “Medication Error Prevention”. 
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Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
28 
 
P 
 
10/25/04 
 
A refill prescription 
for Clonazepam 
0.5mg was 
incorrectly 
dispensed with 
Clonazepam 1mg. 
The prescription 
error was 
discovered by the 
patient and 
subsequently 
corrected. 
 
Incorrect 
Strength 
 
The incorrect strength of 
Clonazepam was 
dispensed at twice the 
prescribed dose. The 
two-fold increase dose 
had the potential to 
cause harm due to the 
risk of side effects such 
as, lethargy, ataxia and 
excessive sedation 
resulting in negative 
outcomes if ingested. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians. 
1) Data Entry Process. New scanners will be utilized to scan hard 
copies of prescriptions.  
2) Prescription verification process. The pharmacist will verify the 
medication filled, verifying the original hard copy of the 
prescription, then verifying the directions and matching the NDC 
numbers of the medication against the NDC numbers of the filled 
medication. 
3) Verification of labels on all containers dispensed. 
4) Patient counseling procedure. Prescription will be reviewed with 
the patient to verify the correct medication and directions. 
5) Communication. Error was shared with all pharmacy personnel. 
6) Submitted an ISMP medication error report. 
7) Completed continuing education on “Medication Error Prevention”. 
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29 
 
IH 
 
11/02/04 
 
A prescription for 
Hydoquinone 4% 
Cream was 
incorrectly 
compounded and 
dispensed 
containing 
sunscreen and 
Hydroquinone 4% 
Cream. 
 
Incorrect 
Strength  
 
A prescription for plain 
Hydroquinone 4% Cream 
was compounded 
incorrectly by adding 
sunscreen and 
Hydroquinone 4% 
Cream. The compound 
resulted in a rash to the 
area applied due to the 
unintended ingredients of 
the compounded cream 
that contained 
sunscreen. The patient 
received medical 
attention and subsequent 
treatment for the rash. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians. 
1) Data Entry Process. New scanners will be utilized to scan hard 
copies of prescriptions. 
2) Prescription verification process. The pharmacist will verify the 
medication filled, verifying the original hard copy of the 
prescription, then verifying the directions and matching the NDC 
numbers of the medication against the NDC numbers of the filled 
medication.  
3) Verification of labels on all containers dispensed. 
4) Patient counseling procedure. Prescription will be reviewed with 
the patient to verify the correct medication and directions. 
5) Communication. Error was shared with all pharmacy personnel. 
6) Submitted an ISMP medication error report. 
7) Completed continuing education on “Medication Error Prevention”. 
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30 
 
IH 
 
10/01/04 
 
A prescription for 
Allopurinol 300mg/ 
Take one tablet a 
day, was incorrectly 
dispensed with 
Allopurinol 300mg/ 
Take one tablet four 
times a day. A dose 
of 1200mg daily was 
ingested rather than 
the intended 300mg 
daily dose. 
 
Incorrect 
Directions 
 
The incorrect directions 
on this prescription for 
resulted in ingestion for 
an 87-year-old patient for 
approximately one week. 
The patient experienced 
side effects from the four-
fold increase in dose of 
Allopurinol (1200mg daily 
rather than 300mg daily), 
including constant thirst, 
lethargy, disruptive sleep 
and overall discomfort 
requiring a visit to the 
physician. The physician 
discovered the error and 
treated the patient 
accordingly. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) Prescription verification process. The pharmacist will verify the 
medication filled, verifying the original hard copy of the 
prescription, then verifying the directions and matching the NDC 
numbers of the medication against the NDC numbers of the filled 
medication.  
2) Reviewed the Drug Utilization (DUR) policy for minimum/maximum 
dose check and to match medication with diagnosis. 
3) Patient counseling procedure. Prescription will be reviewed with 
the patient to verify the correct medication and directions. 
4) Communication. Error was shared with all pharmacy personnel 
5) Submitted an ISMP medication error report. 
6) Completed continuing education on “Medication Error Prevention”. 
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31 
 
P 
 
11/17/04 
 
A prescription for 
Atenolol 25mg, a 
beta-blocker utilized 
for hypertension, 
was incorrectly 
dispensed with 
Atenolol 50mg 
tablets. 
 
Incorrect 
Strength 
 
A prescription was 
incorrectly dispensed 
with a two-fold increase 
in dose of the intended 
medication. A two-fold 
increase in dose can 
result in lowered blood 
pressure.  
Note:  The refill for this 
prescription was filled 
with the incorrect amount 
of tablets (30) rather than 
the prescribed 60 tablets. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians. 
1) Data Entry Process. All patient demographic information is verified 
at prescription drop off. Hard copy prescriptions are scanned into 
the computer system 
2) Prescription verification process. The scan image of medication is 
checked with the dispensed medications, if no image is available 
the actual stock medication stock bottle utilized for verification. The 
pharmacist will verify the medication filled, verifying the original 
hard copy of the prescription, then verifying the directions and 
matching the NDC numbers of the medication against the NDC 
numbers of the filled medication. 
3) Verification of labels on all containers dispensed. 
4) Patient counseling procedure. Prescription will be reviewed with 
the patient to verify the correct medication and directions. 
5) Communication. Error was shared with all pharmacy personnel. 
6) Submitted an ISMP error report. 
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32 
 
I 
 
08/05/04 
 
A prescription for 
Darvocet N-100mg, 
an analgesic, was 
incorrectly 
dispensed with 
Doxycyline 100mg, 
an antibiotic. 
 
Incorrect 
Medication
 
A prescription for 
Darvocet N-100mg was 
received as a verbal 
order from a prescriber 
and reduced to writing by 
a pharmacist using the 
abbreviation "DCN-100", 
which abbreviation was 
mistaken to indicate  
“Doxycycline 100mg” by 
the filling pharmacist. The 
90-year-old patient 
ingested two doses of 
Doxycycline 100mg prior 
to discovery by a family 
member. The potential 
for harm exists if the 
patient developed 
photosensitivity or was 
allergic to Doxycycline. 
Unintended side effects 
or reactions could also 
occur if the medication is 
taken over an extended 
period. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) Data Entry Process. Abbreviations will not be used on call-in 
prescriptions. 
2) Prescription verification process. The pharmacist will verify the 
original prescription hard copy, directions are relevant to the 
medication dispensed i.e. the directions for Darvocet N-100mg are 
not relevant for the antibiotic Doxycycline. Match the NDC 
numbers. 
3) Verification of labels on all containers dispensed. 
4) Patient counseling. Prescription will be reviewed with the patient to 
verify the correct medication and directions. 
5) Communication. Error was shared with all pharmacy personnel. 
6) Submitted an ISMP medication error report. 
7) Completed continuing education on “Medication Error Prevention”. 
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33 
 
IH 
 
11/24/04 
 
A prescription for 
Chlorpromazine 
100mg, an 
antipsychotic 
utilized to control 
schizophrenia and 
negative behaviors, 
was incorrectly 
dispensed with 
Chlorpropamide 
100mg, a 
hypoglycemic 
utilized to control 
elevated blood 
sugar in diabetic 
patients.  
 
Incorrect 
Medication
 
The patient received the 
incorrect medication 
Chlorpropamide 100mg 
for a month, resulting in 
uncontrolled behaviors 
due to the lack of 
antipsychotic medication 
Chlorpromazine 100mg 
treatment and possibly 
due to low blood sugars 
caused by the 
Chlopropamide.   
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians. 
Identified root contributors:  
• The pharmacy’s computer system abbreviated the first eight 
characters of the drug name that are the identical.  
• The drug names sound alike. 
• The physician’s prescription misspelled the drug.  
 
1) Data Entry Process. All patient demographic information is verified 
at prescription drop off. 
2) Prescription verification process. The cause of this QRE was 
determined to be a breakdown in the verification process checking 
the hard copy prescription. The drug name was entered incorrectly 
and the remaining verification process could not be completed 
properly. 
3) Verification of labels on all containers dispensed. 
4) Communication. Error was shared with all pharmacy personnel. 
5) Submitted an ISMP medication error report. 
6) Completed CEUs on “Medication Error Prevention”. 
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Patient Outcomes 
 
Corrective Actions  
 
34 
 
IH 
 
04/16/04 
 
A prescription for 
Tri-Sprintec tablets 
was incorrectly 
dispensed with 
Sprintec tablets. 
Both medications 
contain ethinyl 
estradiol and 
norgestimate at 
different strengths 
and are not 
interchangeable. 
Tri-Sprintec and 
Sprintec are 
classified as birth 
control pills; 
however, they may 
be utilized to control 
adrenal disease by 
some 
endocrinologists.  
 
Incorrect 
Medication
 
A prescription was 
incorrectly dispensed 
with Sprintec rather than 
Tri-Sprintec as 
prescribed to control 
symptoms associated 
with adrenal disease. The 
patient ingested 
approximately a 30-day 
supply prior to discovery 
when the prescription 
was refilled. The patient 
required a follow-up visit 
with the endocrinologist. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) Prescription verification process. The pharmacist will verify the 
medication filled, verifying the original hard copy of the 
prescription, then verifying the directions and matching the NDC 
numbers of the medication against the NDC numbers of the filled 
medication. 
2) Verification of labels on all containers dispensed utilizing bar code 
scanning technologies will be followed.  
3) Patient counseling procedure. Prescription will be reviewed with 
the patient to verify the correct medication and directions. 
4) Communication. Error was shared with all pharmacy personnel. 
5) Submitted an ISMP medication error report. 
6) Completed continuing education on “Medication Error Prevention”. 
  
APPENDIX D: Analysis of Quality Related Event (Medication Error) Reports Reviewed by the Massachusetts Board of Registration in Pharmacy 
 
 
Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
35 
 
I 
 
05/07/04 
 
A prescription for 
Wellbutrin SR 
100mg was 
incorrectly 
dispensed with 
Wellbutrin SR 
150mg. Wellbutrin 
SR is classified as 
an antidepressant. 
 
Incorrect 
Strength 
 
The incorrectly dispensed 
Wellbutrin SR 150mg 
rather than Wellbutrin SR 
100mg, represented a 
dose increase of 50% 
over the intended 
prescribed dose. 
Ingestion of the incorrect 
strength occurred for 30 
days prior to discovery 
when the prescription 
was refilled. The 
unintended side effects 
from a 50% increased 
dose of Wellbutrin SR 
over a 30-day period 
range from mild to 
severe.  
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians. 
1) Adherence to basket system.  Hard copy of the original 
prescription will be placed in basket through filling process. 
2) Medications dispensed from stock bottles are entered into the 
computer so the stock bottle can be verified. 
3) Stock bottle remains in the basket throughout the dispensing 
process. 
4) The stock bottle is checked against the hard copy prescription and 
printed label. 
5) Imaging scanning is checked with all prescriptions. 
6) Completed continuing education on “Medication Error Prevention”. 
7) Submitted ISMP medication error report. 
 
  
APPENDIX D: Analysis of Quality Related Event (Medication Error) Reports Reviewed by the Massachusetts Board of Registration in Pharmacy 
 
 
Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
36 
 
P 
 
03/11/04 
 
A prescription for 
Dilantin Kapseals 
100mg was 
prescribed and 
incorrectly 
dispensed with 
Phenytoin extended 
release 100mg 
capsules. Dilantin 
100mg and 
Phenytoin 100mg 
extended release 
capsules are 
classified as 
anticonvulsants.  
 
Incorrect 
Medication
 
The patient’s neurologist 
prescribed Dilantin 
100mg Kapseals as an 
anticonvulsant to control 
seizures. This brand 
name drug is not 
interchangeable as 
prescribed with any other 
generic medication. The 
pharmacist dispensed a 
generic medication in 
error because standard 
dispensing protocols set 
by the pharmacy were 
not followed. The 
patient’s caregiver 
discovered the error prior 
to ingestion. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians. The pharmacist and 
technicians reviewed standard prescription filling procedures involving 
hard copy verification and product selection when preparing 
prescriptions. 
1) The interchangeable medication policy and regulations were also 
reviewed for this product. 
2) The stock bottle is checked against the hard copy prescription 
and printed label. 
3) Computer upgrade, medications imaging and scanning devices 
are not available at the pharmacy for prescription verification. The 
pharmacy has contacted the software company for upgrades to 
the system such as bar code and imaging scanning for 
prescriptions. 
4) Completed continuing education on “Medication Error 
Prevention”. 
5) Submitted ISMP medication error report. 
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Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
37 
 
I 
 
05/20/04 
 
A prescription for 
Avandia 2mg tablets 
was incorrectly 
dispensed with 
Amaryl 2mg tablets. 
Avandia and Amaryl 
tablets are classified 
as antidiabetic 
agents that have 
different 
mechanisms of 
action and chemical 
structure. 
 
Incorrect 
Medication
 
The patient’s physician 
prescribed Avandia 2mg 
as an antidiabetic agent 
to control elevated blood 
glucose and symptoms of 
diabetes. The patient 
ingested the incorrect 
medication (Amaryl 2mg) 
for 30 days before 
discovery at refill and 
required a follow-up visit 
to the physician. The 
medication prescribed by 
the physician is not 
interchangeable with 
another medication and 
may have negative 
consequences when 
taken for an extended 
period of time. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians  
1) Prescription verification process. The pharmacist will clarify with 
the prescribing physician questions concerning the medication 
prescribed on the original hard copy of the prescription and make 
appropriate corrections. Match the NDC numbers of the 
medication against the NDC numbers of the filled medication. 
2) Verification of labels on all containers dispensed. 
3) Patient counseling procedure, the prescription will be reviewed 
with the patient to verify the correct medication and directions. 
4) Communication. Error was shared with all pharmacy personnel. 
5) Submitted an ISMP medication error report. 
6) Completed continuing education on “Medication Error 
Prevention”. 
  
APPENDIX D: Analysis of Quality Related Event (Medication Error) Reports Reviewed by the Massachusetts Board of Registration in Pharmacy 
 
 
Case # 
 
Category  
of Event 
 
Date 
 
Case Description 
 
Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
38 
 
I 
 
05/19/04 
 
A prescription for 
Fluphenazine 10mg 
tablets, an 
antipsychotic, was 
incorrectly 
dispensed with 
Trihexyphenidyl 
2mg tablets, an 
anticholinergic.  
 
Incorrect 
Medication 
 
The patient’s physician 
prescribed Fluphenazine 
10mg twice daily as an 
antipsychotic. The patient 
ingested 21 doses of the 
incorrect medication 
Trihexyphenidyl for 
approximately ten days 
before discovery by a 
healthcare provider. The 
patient was evaluated at 
a hospital. The potential 
for harm exists due to the 
lack of treatment with the 
intended prescribed 
antipsychotic medication 
for a ten-day period and 
exposure to an 
unintended medication.  
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) Medication Labeling. Medication labeling system has been 
changed to allow only a pharmacist to print labels for medication 
requested. 
2) Labeling.  Only a pharmacist will affix labels for blister card 
medication. The labels are self-adhesive; the pharmacist must also 
secure the label with 2 staples to ensure that there is no transfer of 
labels from one blister card to another. 
3) Barcode scanning.  The barcode on the label will be checked 
against the barcode on the stock bottle. 
4) Drug utilization. The patient’s medication profile is checked for 
duplicate therapy, allergies and medication interactions. 
5) Submitted an ISMP medication error report. 
6) Completed continuing education on “Medication Error Prevention”. 
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of Event 
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Type of 
Error 
 
Patient Outcomes 
 
Corrective Actions  
 
39 
 
IH 
 
06/28/04 
 
A prescription for 
Relafen 500mg 
tablets, an anti-
inflammatory agent, 
was incorrectly 
dispensed with 
Methocarbamol 
500mg tablets, a 
muscle-relaxing 
agent. 
 
Incorrect 
Medication
 
The patient’s physician 
prescribed Relafen 
500mg tablets an anti-
inflammatory to treat 
arthritis. The patient 
ingested the incorrect 
medication 
Methocarbamol for one-
day before becoming ill 
with symptoms of 
lethargy, weakness and 
mild nausea. The patient, 
a nurse who had taken 
the medication several 
years, discovered the 
error by checking the 
Physician’s Desk 
Reference (PDR). The 
potential for harm exists 
due to the lack of 
treatment with the 
prescribed Relafen for a 
three-day period and 
exposure to an 
unintended medication 
that resulted in side 
effects. 
 
The following medication use processes were reviewed and corrected 
by the pharmacy, pharmacists and technicians.  
1) Patient Counseling. The pharmacy reviewed the procedures and 
regulation pertaining to patient counseling. All questions pertaining 
to medication are to be directed to the pharmacist. 
2) Prescription Verification Process. The pharmacist will verify the 
original prescription hard copy against the labeled vial for 
appropriate medication, patient, dose and directions relevant to the 
medication dispensed The barcode on the label will be checked 
against the barcode on the stock bottle. 
3) Communication. Error was shared with all pharmacy personnel. 
4) Submitted an ISMP medication error report. 
5) Completed continuing education on “Medication Error Prevention”. 
 
 
